var title_f7_38_7776="Brow posterior presentation";
var content_f7_38_7776=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69371&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Brow posterior presentation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 397px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dystocia Caused by Abnormalities in Presentation, Position, or Development of the Fetus. In: Williams Obstetrics, 16th Edition, Pritchard, JA, MacDonald, PC (Eds), Appleton-Century-Crofts, New York 1980. p.812. Copyright &copy; 1980 McGraw Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_38_7776=[""].join("\n");
var outline_f7_38_7776=null;
var title_f7_38_7777="HAE wallet card";
var content_f7_38_7777=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F62004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F62004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    Hereditary angioedema emergency care wallet card",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 496px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_38_7777=[""].join("\n");
var outline_f7_38_7777=null;
var title_f7_38_7778="Acitretin xerosis";
var content_f7_38_7778=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acitretin-induced xerosis and desquamation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 404px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diffuse xerosis in a kidney transplant recipient who received 50 mg per day of acitretin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_38_7778=[""].join("\n");
var outline_f7_38_7778=null;
var title_f7_38_7779="Shoulder dystocia documentation form A";
var content_f7_38_7779=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54369%7EOBGYN%2F70280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54369%7EOBGYN%2F70280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 503px\">",
"   <div class=\"ttl\">",
"    Documentation of delivery complicated by shoulder dystocia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 483px; height: 636px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Documentation of delivery complicated by shoulder dystocia, continued",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 601px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_38_7779=[""].join("\n");
var outline_f7_38_7779=null;
var title_f7_38_7780="Calcium acetate: Patient drug information";
var content_f7_38_7780=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Calcium acetate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/48/39685?source=see_link\">",
"     see \"Calcium acetate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/51/21301?source=see_link\">",
"     see \"Calcium acetate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Eliphos&trade;;",
"     </li>",
"     <li>",
"      PhosLo&reg;;",
"     </li>",
"     <li>",
"      Phoslyra&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4663225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PhosLo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12855546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691408",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower high phosphate levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701689",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to calcium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: High calcium levels, kidney stones, or low phosphate levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697716",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Try to space other drugs from this one by 2 hours. This drug stops many drugs from getting into the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3521612",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take iron or zinc within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695910",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11300 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-122.72.76.133-D6C6C51ACA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_38_7780=[""].join("\n");
var outline_f7_38_7780=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144308\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4663225\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12855546\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014183\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014182\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014187\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014188\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014190\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014185\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014186\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014191\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014192\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/48/39685?source=related_link\">",
"      Calcium acetate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/51/21301?source=related_link\">",
"      Calcium acetate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_38_7781="Eating disorders in pregnant women";
var content_f7_38_7781=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Eating disorders in pregnant women",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/38/7781/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/38/7781/contributors\">",
"     Shari I Lusskin, MD, FAPA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/38/7781/contributors\">",
"     Shaila Misri, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/38/7781/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/38/7781/contributors\">",
"     Joel Yager, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/38/7781/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/38/7781/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/38/7781/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/38/7781/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eating disorders, such as anorexia nervosa and bulimia nervosa, refer to significant disturbances in normal eating patterns, body image, and normal weight gain. Anorexia nervosa (",
"    <a class=\"graphic graphic_table graphicRef75110 \" href=\"UTD.htm?9/7/9339\">",
"     table 1",
"    </a>",
"    ) and bulimia nervosa (",
"    <a class=\"graphic graphic_table graphicRef70006 \" href=\"UTD.htm?2/46/2796\">",
"     table 2",
"    </a>",
"    ) may come to medical attention during pregnancy, when weight and eating habits are closely monitored. Changes in body shape and the need to gain weight during pregnancy may be particularly concerning for these women. Anorexia nervosa should be suspected when the patient presents with below normal body weight. Bulimia nervosa, in contrast, has been called \"the invisible eating disorder\" because the patient may have a normal or above normal weight [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7781/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues specific to eating disorders in pregnant women will be reviewed here. A detailed discussion of eating disorders in the general population can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=see_link\">",
"     \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=see_link\">",
"     \"Eating disorders: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE AND COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of eating disorders among women of childbearing potential has been estimated at approximately 4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7781/abstract/2\">",
"     2",
"    </a>",
"    ]. The prevalence in pregnancy, however, appears to be lower [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7781/abstract/1,3-5\">",
"     1,3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postpartum, symptomatic improvement may persist or a relapse may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7781/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The only population-based study on the prevalence and course of eating disorders in pregnant women reported a variable course. The Norwegian Mother and Child Cohort Study assessed the presence of eating disorders in 41,157 pregnant women at approximately 18 weeks of gestation using self-administered questionnaires [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7781/abstract/7\">",
"     7",
"    </a>",
"    ]. Broad criteria were used to define eating disorders, instead of formal DSM-IV criteria. Before pregnancy, anorexia nervosa was diagnosed in 0.1 percent of the women, bulimia nervosa in 0.7 percent, and 3.6 percent had eating disorder not otherwise specified (NOS), which included binge eating disorder and self-induced purging without binge eating. At 18 weeks of gestation, the prevalence of bulimia nervosa fell to 0.2 percent, but the proportion of women with eating disorder NOS increased to 4.9 percent. The prevalence of anorexia nervosa could not be assessed. While some women with bulimia nervosa or eating disorder NOS (purging without binge eating) had partial or complete remission, those with binge eating disorder did not. In fact, binge eating disorder was more likely than other eating disorders to start during pregnancy (incidence 1.12 per 1000 person-weeks, 711 new cases in the study).",
"   </p>",
"   <p>",
"    These findings suggest that for some women, pregnancy is an opportunity for recovery (similar to stopping tobacco or alcohol use), while for others (particularly those with low income), it is a period of vulnerability. The lower prevalence of some eating disorders noted in this and other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7781/abstract/8-10\">",
"     8-10",
"    </a>",
"    ] may reflect symptom remission, under-reporting by patients, or impaired fertility.",
"   </p>",
"   <p>",
"    Clinically, we have observed that few women with active eating disorders improve during pregnancy. Women with restrictive behaviors tend to gain little weight in pregnancy. These women need to be monitored closely and may benefit from nutritional counseling. Women with bulimia nervosa or binge eating disorder often gain excessive weight during pregnancy. The two most likely explanations for this observation are that some women stop their compensatory behaviors (excessive exercise, purging) during pregnancy, and others feel that pregnancy is a license to eat whatever they want, without regard to their weight.",
"   </p>",
"   <p>",
"    In addition, mortality may be lower among patients with anorexia nervosa who give birth to at least one child, compared with patients who remain nulliparous. In a population based study of 5251 patients with anorexia nervosa, all cause mortality (after controlling for several factors, including number of hospitalizations for anorexia nervosa as well as general medical and psychiatric history) was reduced in parous patients compared with nulliparous patients by approximately 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7781/abstract/11\">",
"     11",
"    </a>",
"    ]. However, mortality was higher for both groups of patients compared with the general population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREGNANCY OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disordered eating and the associated compensatory behaviors (eg, purging, vomiting) pose risks for both mother and fetus. Anorexia nervosa predisposes to fetal growth restriction, as well as maternal malnutrition. Observational studies have reported a greater frequency of hyperemesis gravidarum, miscarriage, preterm birth (PTB), cesarean delivery, and postpartum depression in women with eating disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7781/abstract/4,6,12-18\">",
"     4,6,12-18",
"    </a>",
"    ]. For example:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective study compared the pregnancy outcome of 302 women hospitalized with an eating disorder before pregnancy to 900 women without an eating disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7781/abstract/17\">",
"       17",
"      </a>",
"      ]. Women with a history of an eating disorder had significantly higher rates of small for gestational (SGA) infants and PTB (SGA 19.6 versus 12.0 percent, PTB 7.0 versus 4.3 percent). Women who were hospitalized with an eating disorder more than eight years prior to conception were at similar risk to those with recent diagnoses.",
"     </li>",
"     <li>",
"      A prospective cohort study compared the pregnancy outcome of all primiparous women discharged from Swedish hospitals with a diagnosis of anorexia nervosa from 1973 to 1996 and who gave birth from 1983 to 2002 (n = 1000) to primiparous women without anorexia (n = 827,582) who gave birth during the same years [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7781/abstract/19\">",
"       19",
"      </a>",
"      ]. Infants of women with a history of anorexia had a slightly lower mean birth weight than infants of controls. Preeclampsia, instrumental delivery, PTB, SGA, Apgar scores, and perinatal mortality were similar in both groups.",
"     </li>",
"     <li>",
"      The Norwegian Mother and Child Cohort Study discussed above evaluated pregnancy outcome in 1812 pregnant women with binge eating disorder, as well as 304 pregnant women with bulimia nervosa, 35 pregnant women with anorexia nervosa, and 36 pregnant women with purging type eating disorders not otherwise specified in the six months before or during pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7781/abstract/20\">",
"       20",
"      </a>",
"      ]. Pregnancy outcome was compared with that of 33,742 women with no eating disorder. Women with any type of eating disorder were more likely to smoke than women with no eating disorder. Binge eating mothers had higher birth weight infants, a lower risk of small for gestational age infants, and a higher risk of large for gestational age infants and cesarean delivery than women with no eating disorder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis is based upon the definitions in the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (",
"    <a class=\"graphic graphic_table graphicRef75110 \" href=\"UTD.htm?9/7/9339\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef70006 \" href=\"UTD.htm?2/46/2796\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Obstetricians should ask all patients about a history of eating disorders and about current symptoms. Women with anorexia or bulimia tend to conceal their abnormal eating patterns and use compensatory behaviors (fasting, laxative abuse, diuretic abuse, purging, or excessive exercise) because of denial, shame,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    guilt [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7781/abstract/21\">",
"     21",
"    </a>",
"    ]. Some examples of useful questions include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is she concerned about her shape or weight?",
"     </li>",
"     <li>",
"      Does she feel guilty about her eating habits?",
"     </li>",
"     <li>",
"      Does she go on eating binges or feel she has lost control over how much she eats?",
"     </li>",
"     <li>",
"      Does she consciously try to restrict what she eats, or has she made herself vomit to control her weight?",
"     </li>",
"     <li>",
"      Has she ever abused laxatives or diuretics?",
"     </li>",
"     <li>",
"      What are her exercise habits?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=see_link\">",
"     \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Warning signs that pregnant women may have an eating disorder include [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7781/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hyperemesis gravidarum [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7781/abstract/6,13\">",
"       6,13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lack of weight gain over two consecutive prenatal visits in the second trimester",
"     </li>",
"     <li>",
"      History of an eating disorder",
"     </li>",
"     <li>",
"      Unexplained hyperkalemia or other electrolyte abnormalities from use of laxatives",
"     </li>",
"     <li>",
"      Dental problems indicative of poor dental enamel from frequent emesis",
"     </li>",
"     <li>",
"      Abnormal body mass index",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Laboratory tests are of limited utility in making a diagnosis, but may be helpful to exclude other medical illness associated with weight loss. The initial laboratory evaluation for the patient with an eating disorder includes a complete blood count for anemia and electrolytes, blood urea nitrogen, and creatinine if the patient is dehydrated or purging is suspected. Additional testing depends upon the review of systems and the need to exclude other diagnoses (including pregnancy in women not already known to be pregnant). As with all psychiatric disorders, we recommend obtaining a urine toxicology screen to rule out substance abuse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=see_link&amp;anchor=H15#H15\">",
"     \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\", section on 'Medical evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Prepregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eating disorders cause menstrual irregularities, including secondary amenorrhea. Some women with eating disorders may assume that they are infertile because of menstrual irregularities and, therefore may not use contraception: this could lead to unplanned pregnancies. Other women may initially present requesting fertility evaluation and treatment. Ideally, eating disorders should be in full remission before any assisted reproductive technology is initiated to minimize the effects of the disorder on fertility and pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7781/abstract/13,22\">",
"     13,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific treatment of eating disorders is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=see_link\">",
"     \"Eating disorders: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anorexia nervosa and bulimia nervosa are complicated disorders to treat in pregnancy. The dietary habits of affected women must be carefully monitored to ensure adequate weight gain and fetal growth. Nutritional guidance should be provided. She should be asked about use of drugs potentially harmful in pregnancy, including appetite suppressants, diuretics, and excess use of laxatives.",
"   </p>",
"   <p>",
"    Pregnant women with eating disorders require careful evaluation for co-morbid psychiatric disorders such as antenatal depression. Pharmacotherapy with adjunctive psychotherapy is often necessary. Team management is essential, combining the expertise of a nutritionist, the obstetrical provider, and a psychiatrist. Severely ill patients will also need referral to a comprehensive eating disorders program. Coordination of care must continue into the postpartum period, and should include the pediatrician because women with eating disorders are more likely to underfeed their babies than women without eating disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7781/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The high incidence of relapse after delivery, as well as the co-morbidity with postpartum depression mandate careful long-term follow-up of those patients identified in pregnancy.",
"   </p>",
"   <p>",
"    Particular attention should also be paid to calcium supplementation since affected women may be osteopenic prior to conception and the ensuring pregnancy will exacerbate bone loss. This can be further exacerbated by prolonged lactation and multifetal gestations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/25/6553?source=see_link\">",
"     \"Epidemiology and etiology of premenopausal osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anorexia nervosa (",
"      <a class=\"graphic graphic_table graphicRef75110 \" href=\"UTD.htm?9/7/9339\">",
"       table 1",
"      </a>",
"      ) should be suspected when the patient presents with below normal body weight. Women with bulimia nervosa (",
"      <a class=\"graphic graphic_table graphicRef70006 \" href=\"UTD.htm?2/46/2796\">",
"       table 2",
"      </a>",
"      ) may have a normal or above normal weight. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis and evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obstetricians should ask all patients about a history of eating disorders and determine if symptoms are present currently. Eating disorders may be reactivated in pregnancy, and current symptoms may not be divulged freely. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis and evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Signs of an eating disorder in pregnancy include hyperemesis gravidarum, lack of weight gain over two consecutive prenatal visits in the second trimester, and history of an eating disorder. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnosis and evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common pregnancy complications are low birth weight and preterm birth. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pregnancy outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Team management during pregnancy and postpartum is essential, combining the expertise of a nutritionist, the obstetrical care provider, the psychiatrist, and the pediatrician (postpartum). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7781/abstract/1\">",
"      Mitchell-Gieleghem A, Mittelstaedt ME, Bulik CM. Eating disorders and childbearing: concealment and consequences. Birth 2002; 29:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7781/abstract/2\">",
"      King MB. Eating disorders in a general practice population. Prevalence, characteristics and follow-up at 12 to 18 months. Psychol Med Monogr Suppl 1989; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7781/abstract/3\">",
"      Turton P, Hughes P, Bolton H, Sedgwick P. Incidence and demographic correlates of eating disorder symptoms in a pregnant population. Int J Eat Disord 1999; 26:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7781/abstract/4\">",
"      Morgan JF, Lacey JH, Sedgwick PM. Impact of pregnancy on bulimia nervosa. Br J Psychiatry 1999; 174:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7781/abstract/5\">",
"      Blais MA, Becker AE, Burwell RA, et al. Pregnancy: outcome and impact on symptomatology in a cohort of eating-disordered women. Int J Eat Disord 2000; 27:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7781/abstract/6\">",
"      Koubaa S, Kouba S, H&auml;llstr&ouml;m T, et al. Pregnancy and neonatal outcomes in women with eating disorders. Obstet Gynecol 2005; 105:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7781/abstract/7\">",
"      Bulik CM, Von Holle A, Hamer R, et al. Patterns of remission, continuation and incidence of broadly defined eating disorders during early pregnancy in the Norwegian Mother and Child Cohort Study (MoBa). Psychol Med 2007; 37:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7781/abstract/8\">",
"      Crow SJ, Agras WS, Crosby R, et al. Eating disorder symptoms in pregnancy: a prospective study. Int J Eat Disord 2008; 41:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7781/abstract/9\">",
"      Rocco PL, Orbitello B, Perini L, et al. Effects of pregnancy on eating attitudes and disorders: a prospective study. J Psychosom Res 2005; 59:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7781/abstract/10\">",
"      Micali N, Treasure J, Simonoff E. Eating disorders symptoms in pregnancy: a longitudinal study of women with recent and past eating disorders and obesity. J Psychosom Res 2007; 63:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7781/abstract/11\">",
"      Papadopoulos FC, Karamanis G, Brandt L, et al. Childbearing and mortality among women with anorexia nervosa. Int J Eat Disord 2013; 46:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7781/abstract/12\">",
"      Franko DL, Spurrell EB. Detection and management of eating disorders during pregnancy. Obstet Gynecol 2000; 95:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7781/abstract/13\">",
"      Abraham S. Sexuality and reproduction in bulimia nervosa patients over 10 years. J Psychosom Res 1998; 44:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7781/abstract/14\">",
"      Bulik CM, Sullivan PF, Fear JL, et al. Fertility and reproduction in women with anorexia nervosa: a controlled study. J Clin Psychiatry 1999; 60:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7781/abstract/15\">",
"      Conti J, Abraham S, Taylor A. Eating behavior and pregnancy outcome. J Psychosom Res 1998; 44:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7781/abstract/16\">",
"      Franko DL, Blais MA, Becker AE, et al. Pregnancy complications and neonatal outcomes in women with eating disorders. Am J Psychiatry 2001; 158:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7781/abstract/17\">",
"      Sollid CP, Wisborg K, Hjort J, Secher NJ. Eating disorder that was diagnosed before pregnancy and pregnancy outcome. Am J Obstet Gynecol 2004; 190:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7781/abstract/18\">",
"      Micali N, Simonoff E, Treasure J. Risk of major adverse perinatal outcomes in women with eating disorders. Br J Psychiatry 2007; 190:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7781/abstract/19\">",
"      Ek&eacute;us C, Lindberg L, Lindblad F, Hjern A. Birth outcomes and pregnancy complications in women with a history of anorexia nervosa. BJOG 2006; 113:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7781/abstract/20\">",
"      Bulik CM, Von Holle A, Siega-Riz AM, et al. Birth outcomes in women with eating disorders in the Norwegian Mother and Child cohort study (MoBa). Int J Eat Disord 2009; 42:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7781/abstract/21\">",
"      Abraham S. Obstetricians and maternal body weight and eating disorders during pregnancy. J Psychosom Obstet Gynaecol 2001; 22:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7781/abstract/22\">",
"      Norr&eacute; J, Vandereycken W, Gordts S. The management of eating disorders in a fertility clinic: clinical guidelines. J Psychosom Obstet Gynaecol 2001; 22:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7781/abstract/23\">",
"      Russell GF, Treasure J, Eisler I. Mothers with anorexia nervosa who underfeed their children: their recognition and management. Psychol Med 1998; 28:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7781/abstract/24\">",
"      Lacey JH, Smith G. Bulimia nervosa. The impact of pregnancy on mother and baby. Br J Psychiatry 1987; 150:777.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4852 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-F0948400E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_38_7781=[""].join("\n");
var outline_f7_38_7781=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE AND COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREGNANCY OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIAGNOSIS AND EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Prepregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/4852\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/4852|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/7/9339\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for anorexia nervosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/46/2796\" title=\"table 2\">",
"      DSM-IV-TR diagnostic criteria for bulimia nervosa",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=related_link\">",
"      Eating disorders: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/25/6553?source=related_link\">",
"      Epidemiology and etiology of premenopausal osteoporosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_38_7782="Ropivacaine: Drug information";
var content_f7_38_7782=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ropivacaine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/18/40227?source=see_link\">",
"    see \"Ropivacaine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/59/10165?source=see_link\">",
"    see \"Ropivacaine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F219215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Naropin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F219216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Naropin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F219245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Local Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F219219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose varies with procedure, onset and depth of anesthesia desired, vascularity of tissues, duration of anesthesia, and condition of patient",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Surgical anesthesia:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lumbar epidural: 15-30 mL of 0.5% to 1% solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lumbar epidural block for cesarean section:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     20-30 mL dose of 0.5% solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     15-20 mL dose of 0.75% solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thoracic epidural block: 5-15 mL dose of 0.5% or 0.75% solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Major nerve block:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     35-50 mL dose of 0.5% solution (175-250 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     10-40 mL dose of 0.75% solution (75-300 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Field block: 1-40 mL dose of 0.5% solution (5-200 mg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Labor pain management:",
"     </b>",
"     Lumbar epidural: Initial: 10-20 mL 0.2% solution; continuous infusion dose: 6-14 mL/hour of 0.2% solution with incremental injections of 10-15 mL/hour of 0.2% solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Postoperative pain management:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peripheral nerve block: Continuous infusion dose: 5-10 mL/hour of 0.2% solution (Bagry, 2008; Klein, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lumbar or thoracic epidural: Continuous infusion dose: 6-14 mL/hour of 0.2% solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infiltration/minor nerve block:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-100 mL dose of 0.2% solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-40 mL dose of 0.5% solution",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F219220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F219198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Naropin&reg;: 2 mg/mL (10 mL, 20 mL, 100 mL, 200 mL); 5 mg/mL (20 mL, 30 mL, 100 mL, 200 mL); 7.5 mg/mL (20 mL); 10 mg/mL (10 mL, 20 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F219185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F219200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administered via local infiltration, epidural block and epidural infusion, or intermittent bolus",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F219199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local anesthetic for use in surgery, postoperative pain management, and obstetrical procedures when local or regional anesthesia is needed",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F219253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ropivacaine may be confused with bupivacaine, rOPINIRole",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (epidural administration) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F219243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (dose-related and age-related: 32% to 69%), bradycardia (6% to 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (11% to 29%), vomiting (7% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (7% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension, tachycardia, chest pain (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (3% to 9%), headache (5% to 8%), dizziness (3%), chills (2% to 3%), anxiety (1%), lightheadedness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary retention (1% to 5%), urinary tract infection (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (2% to 6%), hypoesthesia, rigors, circumoral paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Oliguria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Shivering",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Accidental I.V. injection (0.2%), angioedema, allergic reaction, apnea (usually associated with epidural block in head/neck region), bronchospasm, cardiac arrest, cardiovascular collapse, chondrolysis (continuous intra-articular administration), dyskinesia, hallucination, hyperthermia, laryngeal edema, myocardial depression, MI, rash, seizure, syncope, tinnitus, urticaria, ventricular arrhythmia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F219203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ropivacaine, amide-type local anesthetics (eg, bupivacaine, mepivacaine, lidocaine), or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F219189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS toxicity: Careful and constant monitoring of the patient's state of consciousness should be done following each local anesthetic injection; at such times, restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression, or drowsiness may be early warning signs of CNS toxicity. Treatment is primarily symptomatic and supportive.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intra-articular infusion related chondrolysis: Continuous intra-articular infusion of local anesthetics after arthroscopic or other surgical procedures is",
"     <b>",
"      not",
"     </b>",
"     an approved use; chondrolysis (primarily in the shoulder joint) has occurred following infusion, with some cases requiring arthroplasty or shoulder replacement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory arrest: Local anesthetics have been associated with rare occurrences of sudden respiratory arrest.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Convulsions due to systemic toxicity leading to cardiac arrest have also been reported, presumably following unintentional intravascular injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with hypotension, hypovolemia, heart block, or cardiovascular disease; may be at greater risk for toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; may be at greater risk for toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurological disorders: Use with caution in patients with neurological disorders; may be at greater risk for toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disorders: Use with caution in patients with psychiatric disorders; may be at greater risk for toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Type III antiarrhythmics: Use with caution in patients on type III antiarrhythmics (eg, amiodarone); consider ECG monitoring since cardiac effects may be additive.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acutely ill patients: Use with caution in acutely ill;  may be at greater risk for toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patient; may be at greater risk for toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly: may be at greater risk for toxicity. Cardiovascular adverse events (bradycardia, hypotension) may be age-related (more common in patients &gt;61 years of age).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Intravascular injections should be avoided; aspiration should be performed prior to administration; the needle must be repositioned until no return of blood can be elicited by aspiration; however, absence of blood in the syringe does not guarantee that intravascular injection has been avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rapid administration: Ropivacaine is not recommended for use in emergency situations where rapid administration is necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Trained personnel: Clinicians using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F219240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2B6 (minor), CYP2D6 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F219194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ciprofloxacin (Systemic): May decrease the metabolism of Ropivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FluvoxaMINE: May decrease the metabolism of Ropivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fospropofol: May increase the serum concentration of Ropivacaine. Specifically, propofol (the active metabolite of fospropofol) is the entity with the potential to interact with ropivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: May enhance the adverse/toxic effect of Local Anesthetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propofol: May increase the serum concentration of Ropivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F219196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F219205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic events were not observed in animal studies. When used for epidural block during labor and delivery, systemically absorbed ropivacaine may cross the placenta, resulting in varying degrees of fetal or neonatal effects (eg, CNS or cardiovascular depression). Fetal or neonatal adverse events include fetal bradycardia (12%), neonatal jaundice (8%), low Apgar scores (3%), fetal distress (2%), neonatal respiratory disorder (3%). Maternal hypotension may also result from systemic absorption. In cases of hypotension, position pregnant woman in left lateral decubitus position to prevent aortocaval compression by the gravid uterus. Epidural anesthesia may prolong the second stage of labor.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F219221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Naropin Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (100 mL): $38.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/mL (30 mL): $26.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg/mL (20 mL): $22.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (10 mL): $13.62",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3341407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, blood pressure, ECG monitoring (if used with antiarrhythmics)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F219206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Narop (IL, SE);",
"     </li>",
"     <li>",
"      Naropeine (FR, GR, PT);",
"     </li>",
"     <li>",
"      Naropin (AE, AR, AT, AU, BB, BE, BH, BM, BR, BS, BZ, CH, CL, CN, CO, CY, CZ, DE, DK, EG, ES, FI, GB, GY, HK, HN, ID, IE, IQ, IR, JM, JO, KP, KW, LB, LU, LY, MX, MY, NL, NO, NZ, OM, PH, PL, QA, RU, SA, SG, SR, SY, TH, TR, TT, VE, YE);",
"     </li>",
"     <li>",
"      Naropina (IT);",
"     </li>",
"     <li>",
"      Ropica (TW);",
"     </li>",
"     <li>",
"      Ropiva (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F219188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F219202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Anesthesia (route dependent): 3-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration (dose and route dependent): 3-15 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, via CYP1A2 to metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Epidural: 5-7 hours; I.V.: Terminal: 111 &plusmn; 62 minutes (Lee, 1989)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (86% as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alahuhta S, Rasanen J, Jouppila P, et al, &ldquo;The Effects of Epidural Ropivacaine and Bupivacaine for Cesarean Section on Uteroplacental and Fetal Circulation,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1995, 83(1):23-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/38/7782/abstract-text/7605013/pubmed\" id=\"7605013\" target=\"_blank\">",
"        7605013",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagry H, de la Cuadra Fontaine JC, Asenjo JF, et al, \"Effect of a Continuous Peripheral Nerve Block on the Inflammatory Response in Knee Arthroplasty,\"",
"      <i>",
"       Reg Anesth Pain Med",
"      </i>",
"      , 2008, 33(1):17-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/38/7782/abstract-text/18155052/pubmed\" id=\"18155052\" target=\"_blank\">",
"        18155052",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Corcoran W, Butterworth J, Weller RS, et al, \"Local Anesthetic-Induced Cardiac Toxicity: A Survey of Contemporary Practice Strategies Among Academic Anesthesiology Departments,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2006, 103(5):1322-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/38/7782/abstract-text/17056977/pubmed\" id=\"17056977\" target=\"_blank\">",
"        17056977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Datta S, Camann W, Bader A, et al, &ldquo;Clinical Effects and Maternal and Fetal Plasma Concentrations of Epidural Ropivacaine Versus Bupivacaine for Cesarean Section,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1995, 82(6):1346-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/38/7782/abstract-text/7793647/pubmed\" id=\"7793647\" target=\"_blank\">",
"        7793647",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dix SK, Rosner GF, Nayar M, et al, &ldquo;Intractable Cardiac Arrest Due to Lidocaine Toxicity Successfully Resuscitated With Lipid Emulsion,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2011, 39(4):872-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/38/7782/abstract-text/21263316/pubmed\" id=\"21263316\" target=\"_blank\">",
"        21263316",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Foxall G, McCahon R, Lamb J, et al, \"Levobupivacaine-Induced Seizures and Cardiovascular Collapse Treated With Intralipid,\"",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 2007, 62(5):516-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/38/7782/abstract-text/17448066/pubmed\" id=\"17448066\" target=\"_blank\">",
"        17448066",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klein SM, Grant SA, Greengrass RA, et al, \"Interscalene Brachial Plexus Block With a Continuous Catheter Insertion System and a Disposable Infusion Pump,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 2000, 91(6):1473-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/38/7782/abstract-text/11094003/pubmed\" id=\"11094003\" target=\"_blank\">",
"        11094003",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lee A, Fagan D, Lamont M, et al, &ldquo;Disposition Kinetics of Ropivacaine in Humans,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1989, 69(6):736-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/38/7782/abstract-text/2589653/pubmed\" id=\"2589653\" target=\"_blank\">",
"        2589653",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Litz RJ, Popp M, Stehr SN, et al, &ldquo;Successful Resuscitation of a Patient With Ropivacaine-Induced Asystole After Axillary Plexus Block Using Lipid Infusion,&rdquo;",
"      <i>",
"       Anaesthesia",
"      </i>",
"      , 2006, 61(8):800-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/38/7782/abstract-text/16867094/pubmed\" id=\"16867094\" target=\"_blank\">",
"        16867094",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McClure JH, &ldquo;Ropivacaine,&rdquo;",
"      <i>",
"       Br J Anaesth",
"      </i>",
"      , 1996, 76(2):300-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/38/7782/abstract-text/8777115/pubmed\" id=\"8777115\" target=\"_blank\">",
"        8777115",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mirtallo JM, Dasta JF, Kleinschmidt KC, et al, &ldquo;State of the Art Review: Intravenous Fat Emulsions: Current Applications, Safety Profile, and Clinical Implications,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2010, 44(4):688-700.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/38/7782/abstract-text/20332339/pubmed\" id=\"20332339\" target=\"_blank\">",
"        20332339",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosenblatt MA, Abel M, Fischer GW, et al, \"Successful Use of a 20% Lipid Emulsion to Resuscitate a Patient After a Presumed Bupivacaine-Related Cardiac Arrest,\"",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 2006, 105(1):217-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/38/7782/abstract-text/16810015/pubmed\" id=\"16810015\" target=\"_blank\">",
"        16810015",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scott DB, Lee A, Fagan D, et al, &ldquo;Acute Toxicity of Ropivacaine Compared With That of Bupivacaine,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1989, 69(5):563-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/38/7782/abstract-text/2679230/pubmed\" id=\"2679230\" target=\"_blank\">",
"        2679230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simpson D, Curran MP, Oldfield V, et al, &ldquo;Ropivacaine. A Review of its Regional Anaesthesia and Acute Pain Management,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2005, 65(18): 2675-2717.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wood MB and Rubin AP, &ldquo;A Comparison of Epidural 1% Ropivacaine and 0.75% Bupivacaine for Lower Abdominal Gynecologic Surgery,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1993, 76(6):1274-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/38/7782/abstract-text/8498665/pubmed\" id=\"8498665\" target=\"_blank\">",
"        8498665",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zaric D, Axelsson K, Nydahl P, et al, &ldquo;Sensory and Motor Blockade During Epidural Analgesia With 1%, 0.75%, and 0.5% Ropivacaine - A Double-Blind Study,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1991, 72(4):509-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/38/7782/abstract-text/2006741/pubmed\" id=\"2006741\" target=\"_blank\">",
"        2006741",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9873 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6F4C19BDB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_38_7782=[""].join("\n");
var outline_f7_38_7782=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219215\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219216\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219245\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219219\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219220\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219198\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219185\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219200\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219199\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219253\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219243\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219203\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219189\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219240\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219194\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219196\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219205\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219221\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323799\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3341407\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219206\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219188\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219202\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9873\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9873|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/18/40227?source=related_link\">",
"      Ropivacaine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/59/10165?source=related_link\">",
"      Ropivacaine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_38_7783="Rehabilitation after cardiac transplantation";
var content_f7_38_7783=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rehabilitation after cardiac transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/38/7783/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/38/7783/contributors\">",
"     Ileana L Pi&ntilde;a, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/38/7783/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/38/7783/contributors\">",
"     Sharon A Hunt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/38/7783/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/38/7783/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/38/7783/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In spite of dramatic advances in the survival of cardiac transplant recipients, published reports have consistently shown abnormal levels of functional capacity. Although there is a rapid rise in exercise capacity that occurs at approximately two months post-transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/1\">",
"     1",
"    </a>",
"    ], and many patients return to their normal activities with improved quality of life, exercise function remains 30 to 40 percent below normal [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior studies describing persistently abnormal exercise capacity in the early posttransplant period suggested several possible explanations, including [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Marked deconditioning prior to transplant due to heart failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17847?source=see_link\">",
"       \"Skeletal muscle dysfunction and exercise intolerance in heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgical denervation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Corticosteroid therapy were possible explanations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=see_link\">",
"       \"Glucocorticoid-induced myopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Peripheral vasoconstriction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This section will review issues related to rehabilitation after cardiac transplantation. A more general discussion of cardiac rehabilitation and exercise capacity in patients with heart failure is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3000?source=see_link\">",
"     \"Cardiac rehabilitation in patients with heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7241?source=see_link\">",
"     \"Exercise capacity and VO2 in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXERCISE CAPACITY IN THE POSTTRANSPLANT PERIOD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early after transplantation, most patients have a notable improvement in functional capacity compared to their preoperative condition, although exercise capacity usually remains below normal. Patients who have been very ill prior to transplantation may be severely deconditioned and may not see an improvement in functional capacity early after transplantation. In the years after transplantation, the benefits of improved cardiac function are countered by the natural effects of aging and the impact of therapies associated with the transplant (eg, immunosuppression). Rehabilitation can be of benefit both early and later after transplant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Early",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of cardiac transplant recipients who have participated in cardiac rehabilitation programs have reported improvements in peak oxygen uptake (VO2) from 16.7 to 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per min after 10 weeks of outpatient exercise training [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/6\">",
"     6",
"    </a>",
"    ]. Although these patients have chronotropic incompetence, this does not seem to limit exercise capacity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7241?source=see_link\">",
"     \"Exercise capacity and VO2 in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of cardiac rehabilitation was illustrated in a study which randomized 27 patients within two weeks of cardiac transplantation to a six month structured rehabilitation program or unstructured therapy at home. Compared to the control group, the exercise group had a greater increase in peak oxygen consumption (49 versus 18 percent) and workload (59 versus 18 percent) and a greater reduction in the ventilatory equivalent for carbon dioxide (20 versus 11 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The often inadequate response to home-based exercise training in cardiac transplant recipients differs from that in patients who have undergone coronary artery bypass graft (CABG) surgery. After an early (within three months of surgery) outpatient program of exercise conditioning, patients who have undergone CABG have levels of functional capacity that are similar to those in cardiac transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/3\">",
"     3",
"    </a>",
"    ]. However, bypass patients who continue to exercise in a home-based program can increase exercise capacity further by 25 percent while transplant recipients with the same program increase functional capacity by only 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Long-term",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functional capacity can decrease naturally with age, and an age-dependent decline in peak VO2 has been noted in normal subjects. This decline can be exacerbated in cardiac transplantation patients due to a number of factors including chronic immunosuppressive therapy, particularly corticosteroids which impair proximal muscle strength. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=see_link\">",
"     \"Glucocorticoid-induced myopathy\"",
"    </a>",
"    .) A review of over 1800 patients demonstrated that VO2 tends to increase after the first year after cardiac transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the best data on long-term exercise capacity is a study of 140 patients who underwent repeated treadmill exercise testing up to nine years after heart transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/1\">",
"     1",
"    </a>",
"    ]. In the group as a whole, peak VO2 increased from 14.2",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per kg pretransplant to 21.4",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per kg 11 months after the transplant. When compared to the normal population, peak VO2 was less than 50 percent predicted in 12 percent of patients, 50 to 70 percent predicted in 44 percent, 70 to 90 percent predicted in 31 percent, and greater than 90 percent in only 13 percent. In contrast to the above report, the improvement seen by six months did not change significantly over nine years of follow-up.",
"   </p>",
"   <p>",
"    A number of factors may contribute to the persistently low exercise capacity in most heart transplant recipients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise capacity may be lower in recipients who are on maintenance corticosteroid therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=see_link\">",
"       \"Glucocorticoid-induced myopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The heart rate response to exercise remains subnormal up to five years after transplant, suggesting that there is no functionally significant cardiac reinnervation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with chronic heart failure have skeletal muscle histologic abnormalities with an increase in type II (fast twitch) muscle fibers relative to type I (slower twitch) fibers. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17847?source=see_link\">",
"       \"Skeletal muscle dysfunction and exercise intolerance in heart failure\"",
"      </a>",
"      .) After transplant, the ratio of both fiber types remains unchanged, but a significant increase in fiber size occurs in association with an elevation in skeletal muscle oxidative capacity. Thus, although some of the skeletal muscle abnormalities improve after transplantation, complete normalization does not occur.",
"     </li>",
"     <li>",
"      Neurohormonal abnormalities associated with heart failure do not normalize rapidly after transplantation, and may contribute to persistent post-transplant vasoconstriction [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Data obtained five years posttransplant show that the peak VO2 decreases with time in some patients [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/11\">",
"       11",
"      </a>",
"      ]. However, if measured as an absolute value rather than normalized to body weight, VO2",
"      <span class=\"nowrap\">",
"       (mL/min)",
"      </span>",
"      remains unchanged, suggesting that weight gain impacts negatively on exercise performance.",
"     </li>",
"     <li>",
"      Exercise response in transplant recipients may be limited by reduced preload and heart rate reserve [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/12\">",
"       12",
"      </a>",
"      ]. Transplant recipients generated reduced peak cardiac index due to lower peak heart rate and lower peak end-diastolic volume index as compared to donor age-matched controls. During sustained exercise, end-diastolic volume index and cardiac index were lower in transplant recipients than in controls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Value of later rehabilitation programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac rehabilitation can be of value several years after transplantation. This was illustrated in a series of 21 patients who were five years post-transplant and not engaging in routine physical activity were enrolled in a training program [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/13\">",
"     13",
"    </a>",
"    ]. Endurance exercise capacity increased by 18 and 35 percent at three months and one year, respectively. The increases in exercise and peak VO2 were related to improved aerobic metabolism, rather than improved cardiac performance. Maximum heart rate and stroke volume remained constant, as has been shown in other studies. Early in training, 50 percent of the improvement was due to better skeletal muscle conditioning and the remainder due to increased central responses.",
"   </p>",
"   <p>",
"    Improvements in exercise capacity post-transplant do not seem to be related to ventricular function or to changes in endothelial function. In a trial performed a mean of five years post-transplantation, 43 patients were randomly assigned to a supervised strength and aerobic training program or no training [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/14\">",
"     14",
"    </a>",
"    ]. Peak VO2, total lean mass, and strength improved significantly more in the trained group although submaximal exercise left ventricular systolic function and brachial artery endothelial-dependent or &ndash;independent vasodilation were not significantly improved. Thus, physical conditioning should still be encouraged years after transplantation.",
"   </p>",
"   <p>",
"    The ultimate results of an exercise program depend in part upon the motivation of the individual. In one study, for example, patients underwent a 16 month program at the end of which there was a significant improvement in VO2 in the more compliant patients (32.2 versus 21.3",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per min at baseline) but no significant change in the less compliant patients (24.5 versus 21.8",
"    <span class=\"nowrap\">",
"     mL/kg/min",
"    </span>",
"    at baseline) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/15\">",
"     15",
"    </a>",
"    ]. The overall exercise capacity of the combined group was 70 percent of normal. Nevertheless, the amount of work achieved in both groups increased, as did the peak double product achieved at similar effort levels, measured by the respiratory exchange ratio (RER =",
"    <span class=\"nowrap\">",
"     VCO2/VO2)",
"    </span>",
"    and Borg effort level, ie, the rate of perceived exertion (RPE) (",
"    <a class=\"graphic graphic_table graphicRef70470 \" href=\"UTD.htm?20/13/20699\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=see_link&amp;anchor=H10#H10\">",
"     \"Components of cardiac rehabilitation and exercise prescription\", section on 'Rating of perceived exertion (Borg scale)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     THE TRANSPLANT CARDIAC REHABILITATION PROGRAM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have undergone cardiac transplantation pose a challenge to the cardiac rehabilitation team. Many of these patients been repeatedly hospitalized for prolonged periods of time, leading to marked deconditioning; they are also often cachectic and malnourished due to prior congestive heart failure.",
"   </p>",
"   <p>",
"    Cardiac transplantation offers these patients a new source of central cardiovascular blood flow. For the reasons noted above, the likelihood of restoring exercise capacity is increased with adherence to a cardiac rehabilitation program. Due to persistent sinus node denervation, the heart rate cannot be used as a measure of work intensity; as a result, the rehabilitation team must rely on clinical judgment and the rating of perceived exertion (RPE or Borg scale) to guide exercise therapy (",
"    <a class=\"graphic graphic_table graphicRef70470 \" href=\"UTD.htm?20/13/20699\">",
"     table 1",
"    </a>",
"    ). Alternatively, an empiric workload intensity level can be prescribed, as long as it is accompanied by a plan of progression to higher intensity levels over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pretransplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, cardiac transplant candidates should initiate an exercise program as soon as possible after transplant listing and prior to transplant. The program should include both aerobic training as well as resistive exercise. Aerobic training is safe in patients with heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. Resistive training is not as well studied in this population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3000?source=see_link\">",
"     \"Cardiac rehabilitation in patients with heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the program is instituted pretransplantation, the patient will be familiar with exercise modes such as range of motion and will be able to reinitiate these with minimal re-education shortly after transplantation. Furthermore, if the patient is in a better conditioned state pretransplant, the few days of intubation and inactivity after transplant will do little to reverse this level of conditioning.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For stable outpatients, we recommend exercise as an adjunct to pharmacologic therapy during the entire waiting period. The AHCPR Guidelines on Cardiac Rehabilitation recommend exercise training both prior to and after transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/21\">",
"       21",
"      </a>",
"      ] as does the Exercise and Heart Failure Statement by the American Heart Association and the Scientific Statement on Cardiac Rehabilitation and Secondary Prevention of Coronary Heart Disease [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/19,22,23\">",
"       19,22,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The 2010 Performance Measures for Cardiac Rehabilitation include cardiac transplantation in its A1 inpatient measure for referral. The preferred timing of referral is during the hospital stay for the transplant event. The document also includes an A2 referral for rehabilitation in the outpatient setting for those not referred earlier [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For patients on home inotropic therapy, a monitored program in a cardiac rehabilitation center seems prudent, since inotropes can stimulate or worsen arrhythmias.",
"     </li>",
"     <li>",
"      For those patients who become dependent upon inotropic support therapy and are hospitalized, the same type of program can be instituted in the hospital. A set routine consisting of bicycle, treadmill, upper body ergometry, and free weights can be carried out safely in the controlled intensive care setting. Walking can often dissipate boredom and will add to the patient's functional capacity. The exercise intensity may need to be determined by patient symptoms, rather than by heart rate or RPE.",
"     </li>",
"     <li>",
"      For patients on inotropic support who are being monitored hemodynamically (usually with pulmonary artery catheterization), activity will vary depending upon patient mobility. Certainly, range of motion and leg movement exercises can be performed at the bedside. The addition of incentive spirometry will assure that the ventilatory muscles remain active and trained.",
"     </li>",
"     <li>",
"      Limited data suggest that exercise training may be beneficial in patients who receive a left ventricular assist device (LVAD) as a bridge to transplantation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37785?source=see_link\">",
"       \"Intermediate- and long-term mechanical cardiac support\"",
"      </a>",
"      .) The EVADE pilot trial evaluated 10 patients awaiting transplant who received a TCI LVAD [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/25\">",
"       25",
"      </a>",
"      ]. Supine bicycle exercise, begun 42 days after implantation of the LVAD, was safe, and was not limited by right heart decompensation. During exercise, there was a reduction in right ventricular size and an increase in left ventricular preload. The left ventricle and LVAD work in parallel with the left ventricle actively contributing to the systemic circulation directly through ejection across the aortic valve and indirectly through LVAD filling. The Guidelines on Cardiac Rehabilitation acknowledge that further work is needed since the effect of exercise training in this group is not clear [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/23\">",
"       23",
"      </a>",
"      ]. With the growing role of ventricular assist devices, particularly the non-pulsatile ones, the physiology and rehabilitation of those patients needs to be readdressed. In addition, as LVAD implantation is increasing as a bridge to a decision, particularly in older patients [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/26\">",
"       26",
"      </a>",
"      ], testing for frailty indices may be advisable and better inform a rehabilitation plan prior to transplantation. Both early and late mobilization may improve quality of life in this growing population [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Immediate posttransplantation rehabilitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A series of sequential steps should be initiated in the immediate posttransplant period:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prior to removal of the chest tubes and pacer wires, exercise consists mainly of passive and active range of motion accompanied by incentive spirometry to facilitate pulmonary toilet.",
"     </li>",
"     <li>",
"      Once out of bed in a chair, leg raising and hip girdle exercises become useful as a preparation to transfer weight from sitting to standing.",
"     </li>",
"     <li>",
"      Once the patient is able to stand, ambulation is initiated, initially in the patient room, progressing to the ward. It is assumed at this point that the patient is on telemetry monitoring. Intensity continues to be assessed by rate of perceived exertion, more commonly using the RPE (Borg) scale (",
"      <a class=\"graphic graphic_table graphicRef70470 \" href=\"UTD.htm?20/13/20699\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prior to discharge, if no allograft rejection occurs, the patient may be able to exercise on a stationary bicycle ergometer",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      treadmill. It is our preference to perform a predischarge cardiopulmonary exercise test to better define an exercise prescription for an outpatient program. The rehabilitation team should not be surprised to find a peak VO2 that is very similar to the value pretransplantation due to the deconditioned peripheral musculoskeletal system.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Myopathy and resistance training",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proximal muscle weakness is common in post-transplant patients for a number of reasons, including chronic corticosteroid use and the skeletal muscle changes associated with long-standing heart failure. The value of resistance training was suggested by a randomized controlled trial with 8 patients in the training group and 8 in the control group [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/28\">",
"     28",
"    </a>",
"    ]. Training began two months after surgery to allow sternal healing. The program included both upper and lower body exercises using a set of variable resistance equipment twice weekly for six months. A set consisted of 10 to 15 repetitions at 50 percent of one repetition maximum. After 15 repetitions were successful, the resistance was gradually increased but not to exceed 15 repetitions. The program had no complications.",
"   </p>",
"   <p>",
"    Among patients randomized to resistance training, skeletal muscle fibers shifted from the less oxidative Type II to the more fatigue-resistant Type I. In contrast, patients in the control group, who participated in largely aerobic activity, had a further loss of Type I fibers and an increase in Type II. In addition, resistance training produced greater increases in oxidative and glycolytic skeletal muscle enzymes than aerobic training alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Posthospital exercise prescription",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exercise prescription posttransplantation includes all the essentials of intensity, duration, frequency, and progression. These issues will be reviewed briefly here and are described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=see_link\">",
"     \"Components of cardiac rehabilitation and exercise prescription\"",
"    </a>",
"    .) Patients receiving rehabilitation programs should also be given specific exercise modalities, such as resistance training after the first six weeks posttransplantation, the time required to permit healing of the sternal incision.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intensity &mdash;The RPE at the anaerobic threshold is used to prescribe intensity since the heart rate will not be commensurate to the effort because of cardiac denervation. The anaerobic threshold or ventilatory threshold correlates with the lactate threshold in transplant recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7783/abstract/29\">",
"       29",
"      </a>",
"      ]. Alternatively, an empiric workload intensity level can be prescribed, as long as it is accompanied by a plan of progression to higher intensity levels over time.",
"     </li>",
"     <li>",
"      Duration &mdash; Warm-up and cool down is essential with a minimum of 20 minutes at the prescribed intensity.",
"     </li>",
"     <li>",
"      Frequency &mdash; Exercise should be performed in a supervised setting three times per week for a minimum of six to eight weeks. Some programs are constructed for a 12 week period. A walking program is recommended for alternate days. An extension of this time-table is often necessary to take into account early episodes of rejection or infection which may preclude exercise for several days at a time. There are no studies to indicate that ECG monitoring is required.",
"     </li>",
"     <li>",
"      Progression &mdash; It is important to outline a progressive increase in exercise activity to account for improvement in function which may occur early in the program. An RPE of 11 to 13 often results in early deconditioning (",
"      <a class=\"graphic graphic_table graphicRef70470 \" href=\"UTD.htm?20/13/20699\">",
"       table 1",
"      </a>",
"      ). Thus, every effort should be made to increase the intensity to at least RPE 13 to 15 to approach the ventilatory threshold which may also improve with exercise. If an empiric workload level has been prescribed, a plan of progression to higher intensity levels over time should be incorporated.",
"     </li>",
"     <li>",
"      Resistance exercise &mdash; Although less well studied in transplant recipients, resistance exercise can be performed safely and will increase strength and flexibility for tasks of daily living. As noted above, a gradually incremental resistance program can improve fiber type in skeletal muscle, as well as increase oxidative capacity to enhance work. It is recommended, therefore, that a resistance program be added to the aerobic training regimen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After the initial program of cardiac rehabilitation is completed, a repeat cardiopulmonary exercise test should be performed in order to update the exercise prescription. Patients should be encouraged to adopt exercise and activity as a way of life. Adherence to physical activity should be monitored in a similar fashion to adherence to the medical regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18888990\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early after transplantation, most patients have a notable improvement in functional capacity compared to their preoperative condition, although exercise capacity usually remains below normal. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Early'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although data are limited, cardiac rehabilitation may provide benefit both early and later after transplant. Long term improvement is limited, which may be due to the effects of aging, cardiac denervation, transplant therapy, and prior heart failure. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Exercise capacity in the posttransplant period'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A pretransplantation exercise program is recommended for cardiac transplant candidates to improve patients&rsquo; conditioning and familiarity with physical training in preparation for posttransplantation rehabilitation. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pretransplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Posttransplantation rehabilitation should begin in the immediate post-operative period if possible and should continue and progress as the patient&rsquo;s condition allows. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'The transplant cardiac rehabilitation program'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The posthospital exercise prescription includes targets for intensity, duration, frequency, and progression. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Posthospital exercise prescription'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/1\">",
"      Osada N, Chaitman BR, Donohue TJ, et al. Long-term cardiopulmonary exercise performance after heart transplantation. Am J Cardiol 1997; 79:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/2\">",
"      Degre SG, Niset GL, De Smet JM, et al. Cardiorespiratory response to early exercise testing after orthotopic cardiac transplantation. Am J Cardiol 1987; 60:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/3\">",
"      Daida H, Squires RW, Allison TG, et al. Sequential assessment of exercise tolerance in heart transplantation compared with coronary artery bypass surgery after phase II cardiac rehabilitation. Am J Cardiol 1996; 77:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/4\">",
"      Renlund DG, Taylor DO, Ensley RD, et al. Exercise capacity after heart transplantation: influence of donor and recipient characteristics. J Heart Lung Transplant 1996; 15:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/5\">",
"      Lord SW, Brady S, Holt ND, et al. Exercise response after cardiac transplantation: correlation with sympathetic reinnervation. Heart 1996; 75:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/6\">",
"      Keteyian S, Shepard R, Ehrman J, et al. Cardiovascular responses of heart transplant patients to exercise training. J Appl Physiol 1991; 70:2627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/7\">",
"      Kobashigawa JA, Leaf DA, Lee N, et al. A controlled trial of exercise rehabilitation after heart transplantation. N Engl J Med 1999; 340:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/8\">",
"      Marconi C, Marzorati M. Exercise after heart transplantation. Eur J Appl Physiol 2003; 90:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/9\">",
"      Givertz MM, Hartley LH, Colucci WS. Long-term sequential changes in exercise capacity and chronotropic responsiveness after cardiac transplantation. Circulation 1997; 96:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/10\">",
"      Braith RW, Welsch MA, Feigenbaum MS, et al. Neuroendocrine activation in heart failure is modified by endurance exercise training. J Am Coll Cardiol 1999; 34:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/11\">",
"      Baroud I, Niset G, Vachiery JL, et al. Long-term follow-up of heart transplant patients. Acta Cardiol 1996; 51:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/12\">",
"      Scott JM, Esch BT, Haykowsky MJ, et al. Cardiovascular responses to incremental and sustained submaximal exercise in heart transplant recipients. Am J Physiol Heart Circ Physiol 2009; 296:H350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/13\">",
"      Tegtbur U, Busse MW, Jung K, et al. Time course of physical reconditioning during exercise rehabilitation late after heart transplantation. J Heart Lung Transplant 2005; 24:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/14\">",
"      Haykowsky M, Taylor D, Kim D, Tymchak W. Exercise training improves aerobic capacity and skeletal muscle function in heart transplant recipients. Am J Transplant 2009; 9:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/15\">",
"      Kavanagh T, Yacoub MH, Mertens DJ, et al. Cardiorespiratory responses to exercise training after orthotopic cardiac transplantation. Circulation 1988; 77:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/16\">",
"      Borg G. Perceived exertion as an indicator of somatic stress. Scand J Rehabil Med 1970; 2:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/17\">",
"      Giannuzzi P, Temporelli PL, Tavazzi L, et al. EAMI--exercise training in anterior myocardial infarction: an ongoing multicenter randomized study. Preliminary results on left ventricular function and remodeling. The EAMI Study Group. Chest 1992; 101:315S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/18\">",
"      Giannuzzi P, Tavazzi L, Temporelli PL, et al. Long-term physical training and left ventricular remodeling after anterior myocardial infarction: results of the Exercise in Anterior Myocardial Infarction (EAMI) trial. EAMI Study Group. J Am Coll Cardiol 1993; 22:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/19\">",
"      Pi&ntilde;a IL, Apstein CS, Balady GJ, et al. Exercise and heart failure: A statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. Circulation 2003; 107:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/20\">",
"      O'Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009; 301:1439.",
"     </a>",
"    </li>",
"    <li>",
"     Wenger, NK, Froelicher, ES, Smith, LK, et al. Cardiac Rehabilitation, Clinical Practice Guideline, No. 17, US Department of Health and Human Services, Rockville, MD, Public Health Service, Agency for Health Care Policy and Research, National Heart, Lung, and Blood Institute, AHCPR Publication No. 96-0672, 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/22\">",
"      Whellan DJ, O'Connor CM, Pina I. Training trials in heart failure: time to exercise restraint? Am Heart J 2004; 147:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/23\">",
"      Leon AS, Franklin BA, Costa F, et al. Cardiac rehabilitation and secondary prevention of coronary heart disease: an American Heart Association scientific statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity), in collaboration with the American association of Cardiovascular and Pulmonary Rehabilitation. Circulation 2005; 111:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/24\">",
"      American Association of Cardiovascular and Pulmonary Rehabilitation, American College of Cardiology Foundation, American Heart Association Task Force on Performance Measures (Writing Committee to Develop Clinical Performance Measures for Cardiac Rehabilitation), et al. AACVPR/ACCF/AHA 2010 Update: Performance Measures on Cardiac Rehabilitation for Referral to Cardiac Rehabilitation/Secondary Prevention Services Endorsed by the American College of Chest Physicians, the American College of Sports Medicine, the American Physical Therapy Association, the Canadian Association of Cardiac Rehabilitation, the Clinical Exercise Physiology Association, the European Association for Cardiovascular Prevention and Rehabilitation, the Inter-American Heart Foundation, the National Association of Clinical Nurse Specialists, the Preventive Cardiovascular Nurses Association, and the Society of Thoracic Surgeons. J Am Coll Cardiol 2010; 56:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/25\">",
"      Jaski BE, Kim J, Maly RS, et al. Effects of exercise during long-term support with a left ventricular assist device. Results of the experience with left ventricular assist device with exercise (EVADE) pilot trial. Circulation 1997; 95:2401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/26\">",
"      Weiss ES, Nwakanma LU, Patel ND, Yuh DD. Outcomes in patients older than 60 years of age undergoing orthotopic heart transplantation: an analysis of the UNOS database. J Heart Lung Transplant 2008; 27:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/27\">",
"      Corr&agrave; U, Pistono M, Mezzani A, et al. Cardiovascular prevention and rehabilitation for patients with ventricular assist device from exercise therapy to long-term therapy. Part I: Exercise therapy. Monaldi Arch Chest Dis 2011; 76:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/28\">",
"      Braith RW, Magyari PM, Pierce GL, et al. Effect of resistance exercise on skeletal muscle myopathy in heart transplant recipients. Am J Cardiol 2005; 95:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7783/abstract/29\">",
"      Brubaker PH, Berry MJ, Brozena SC, et al. Relationship of lactate and ventilatory thresholds in cardiac transplant patients. Med Sci Sports Exerc 1993; 25:191.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3527 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-CAE323FBD7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_38_7783=[""].join("\n");
var outline_f7_38_7783=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18888990\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXERCISE CAPACITY IN THE POSTTRANSPLANT PERIOD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Early",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Long-term",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Value of later rehabilitation programs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      THE TRANSPLANT CARDIAC REHABILITATION PROGRAM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pretransplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Immediate posttransplantation rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Myopathy and resistance training",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Posthospital exercise prescription",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18888990\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3527\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3527|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/13/20699\" title=\"table 1\">",
"      Rating of perceived exertion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3000?source=related_link\">",
"      Cardiac rehabilitation in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31417?source=related_link\">",
"      Components of cardiac rehabilitation and exercise prescription",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7241?source=related_link\">",
"      Exercise capacity and VO2 in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/40/23173?source=related_link\">",
"      Glucocorticoid-induced myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37785?source=related_link\">",
"      Intermediate- and long-term mechanical cardiac support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17847?source=related_link\">",
"      Skeletal muscle dysfunction and exercise intolerance in heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_38_7784="Relapse of classical Hodgkin lymphoma after initial radiotherapy";
var content_f7_38_7784=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Relapse of classical Hodgkin lymphoma after initial radiotherapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/38/7784/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/38/7784/contributors\">",
"     George P Canellos, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/38/7784/contributors\">",
"     Peter M Mauch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/38/7784/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/38/7784/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/38/7784/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/38/7784/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/38/7784/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Very few patients with stage I-II Hodgkin lymphoma (formerly called Hodgkin's disease) and favorable prognostic features are treated with radiotherapy alone since the adoption of modified chemotherapy and radiation therapy (RT) as initial treatment. However, some patients initially treated with RT alone will develop late relapse requiring treatment today. Also, some of the principles regarding chemotherapy for relapse in this setting are important for an understanding of the overall treatment of Hodgkin lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11770?source=see_link\">",
"     \"Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 20 to 35 percent of stage I-II patients treated with RT alone experience a relapse of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. The sensitivity to chemotherapy is similar at the time of initial therapy and at the time of relapse, and salvage chemotherapy can achieve durable responses and remissions in approximately 70 percent of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/6\">",
"     6",
"    </a>",
"    ]. This observation explains why, although the relapse rate for favorable prognosis stage I-II Hodgkin lymphoma is higher with radiotherapy alone compared with combined with chemotherapy, survival is similar (",
"    <a class=\"graphic graphic_figure graphicRef75274 \" href=\"UTD.htm?23/10/23726\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presentation, prognostic factors, diagnosis, and treatment of relapse after initial treatment with radiotherapy will be reviewed here. Relapse after systemic therapy is discussed separately as is relapse of nodular lymphocyte predominant HL after initial radiation therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/17/37145?source=see_link\">",
"     \"Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34520?source=see_link\">",
"     \"Treatment of nodular lymphocyte-predominant Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In this discussion, the following definitions will apply:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relapse (or recurrence) is the reappearance of disease in sites of prior disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      in new sites after initial therapy and attainment of complete response.",
"     </li>",
"     <li>",
"      Progression refers to increasing evidence of disease after achieving a stable partial remission.",
"     </li>",
"     <li>",
"      Refractory disease is a failure to achieve a complete or partial response. The refractoriness can be primary (failure to respond to initial therapy) or secondary (initial response but failure to respond after disease relapse).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRESENTATION AND DETECTION OF RELAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up procedures for the detection of relapse after initial treatment vary somewhat from institution to institution. They generally assume a schedule of examination every two to three months for the first two years followed by every four to six months for the next three years, and annually after five years. Most relapses of Hodgkin lymphoma occur within the first three years after diagnosis, but a smaller fraction develop after a longer observation period of up to 10 years or more [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3079?source=see_link\">",
"     \"Long-term follow-up of the patient with classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Detection of relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most recurrences present with symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a mass lesion detected on physical examination. The screening value of procedures other than history and physical examination and possibly chest x-ray is not clear.",
"   </p>",
"   <p>",
"    One report retrospectively reviewed the value of follow-up procedures for the detection of relapse in patients treated for Hodgkin lymphoma with radiation therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/12\">",
"     12",
"    </a>",
"    ]. In this study, relapse occurred in 157 patients at a median of 1.9 years posttreatment. Relapse was suspected primarily by history in 55 percent of patients, physical examination in 14 percent, chest x-ray (CXR) in 23 percent, and abdominal plain film in 7 percent. Another study has questioned the use of routine computed tomography (CT) scans in the surveillance of asymptomatic patients in complete remission after treatment for HL [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sites of relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principles of wide-field radiotherapy for Hodgkin lymphoma are based upon the concept that subclinical disease spreads to adjacent lymph node areas from clinically involved sites [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/14\">",
"     14",
"    </a>",
"    ]. With wide-field irradiation, the large majority of recurrences occur outside the radiation field. The definitions of the radiation fields used in the treatment of Hodgkin lymphoma are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef78652 \" href=\"UTD.htm?27/6/27756\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     In-field relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of proper radiation technique and dose should achieve an in-field disease control rate of 96 to 99 percent. This was illustrated in a report from the Patterns of Care Study of the American College of Radiology [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The risk of recurrence is both field size and dose related. With the use of both chemotherapy and radiation therapy, clinical trials have demonstrated that recurrences are similar with involved and extended field approaches. The efficacy of radiation therapy continues to support its use in patients with localized disease, bulky disease, and in patients who recur on one side of the diaphragm and are planned for high dose chemotherapy and autologous hematopoietic cell transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Site of relapse outside the radiation field",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients present with relapse limited to nodal sites. In a series of 627 patients with pathologic stage (PS) IA-IIIB Hodgkin lymphoma, for example, 138 patients (22 percent) experienced relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/2\">",
"     2",
"    </a>",
"    ]. The site of the first relapse was nodal in 59 percent of these patients. A similar rate of relapse was found in another report of 565 patients with PS I-IIA, I-IIB, or IIIA Hodgkin lymphoma; 109 patients (19 percent) relapsed after primary radiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/3\">",
"     3",
"    </a>",
"    ]. The most frequent site of relapse was the lung (primarily in patients who had presented with large mediastinal masses), which accounted for 26 percent of the relapses. The other sites included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Axillary nodes &mdash; 23 percent",
"     </li>",
"     <li>",
"      Iliac nodes &mdash; 17 percent",
"     </li>",
"     <li>",
"      Mediastinum &mdash; 15 percent",
"     </li>",
"     <li>",
"      Cervical or supraclavicular nodes &mdash; 15 percent",
"     </li>",
"     <li>",
"      Bone &mdash; 10 percent",
"     </li>",
"     <li>",
"      Hilar nodes &mdash; 10 percent",
"     </li>",
"     <li>",
"      Paraaortic nodes &mdash; 9 percent",
"     </li>",
"     <li>",
"      Bone marrow &mdash; 9 percent",
"     </li>",
"     <li>",
"      Epicardial or pericardial &mdash; 6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Late relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late recurrences (more than three years) following radiation therapy occur in 10 to 25 percent of patients, significantly more commonly than seen following combined modality therapy (",
"    <a class=\"graphic graphic_figure graphicRef75274 \" href=\"UTD.htm?23/10/23726\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In a series of 1082 patients from the European Organization for Research and Treatment of Cancer (EORTC), relapse more than five years following radiation therapy for stage I-II Hodgkin lymphoma occurred in 3.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/11\">",
"     11",
"    </a>",
"    ]. If treated, patients with late relapse have the same long-term outcome as patients without late relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/8,11\">",
"     8,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FACTORS FOR RELAPSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been a number of analyses of clinical factors at initial diagnosis which predict outcome after radiotherapy for early stage Hodgkin lymphoma. Tumor burden, defined by stage and bulk of disease, remains the major prognostic factor for predicting outcome after primary treatment with radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Radiation field",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent of the original radiation field has an impact on the pattern of disease at relapse. Even in those patients staged with laparotomy, transdiaphragmatic nodal recurrence can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/18-22\">",
"     18-22",
"    </a>",
"    ]. A meta-analysis of 2366 patients staged with laparotomy and treated with radiotherapy alone was performed by the International Hodgkin's Disease Collaborative Group [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/4\">",
"     4",
"    </a>",
"    ]. Among these patients, 29 percent relapsed, including 86 of 205 (42 percent) treated with involved field, 213 of 741 (29 percent) treated with the extended field, and 376 of 1361 (28 percent) treated with total nodal irradiation.",
"   </p>",
"   <p>",
"    However, meta-analyses of clinical trials show that the extent of the initial radiation fields does not have an impact on overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/7\">",
"     7",
"    </a>",
"    ]. This is due to the success of salvage chemotherapy in those patients who have relapsed after initial radiation treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Stage of disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stage of disease is an important predictor of relapse after radiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/2,23\">",
"     2,23",
"    </a>",
"    ]. Most patients treated with radiotherapy alone have stage I-II disease. As an example, the Harvard Joint Center for Radiation Therapy analyzed a series of 481 patients treated initially with radiotherapy; 16 percent were pathologic stage (PS) IIIA or IIIB [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/2\">",
"     2",
"    </a>",
"    ]. One-hundred-eighteen patients experienced relapse; the frequency of relapse according to stage was as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      PS IA and PS IIA &mdash; 17 percent",
"     </li>",
"     <li>",
"      PS IB and PS IIB &mdash; 31 percent",
"     </li>",
"     <li>",
"      PS IIIA &mdash; 54 percent",
"     </li>",
"     <li>",
"      PS IIIB &mdash; 71 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At present, only patients in the first group are candidates for radiation therapy alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The International Database on Hodgkin's Disease contained statistics on 3750 patients who were initially treated with radiotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/24\">",
"     24",
"    </a>",
"    ]. Relapse occurred in 31 percent. The factors predicting relapse in patients with clinical stage I-II included (",
"    <a class=\"graphic graphic_table graphicRef55166 \" href=\"UTD.htm?33/1/33821\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Histology",
"     </li>",
"     <li>",
"      Number of sites involved",
"     </li>",
"     <li>",
"      Presence of systemic symptoms (eg, fever, night sweats, weight loss)",
"     </li>",
"     <li>",
"      Presence of mediastinal involvement",
"     </li>",
"     <li>",
"      Elevated erythrocyte sedimentation rate",
"     </li>",
"     <li>",
"      Low hemoglobin",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A review of the EORTC experience also indicated that a persistent elevation (above 30",
"    <span class=\"nowrap\">",
"     mm/hr)",
"    </span>",
"    in the erythrocyte sedimentation rate was highly correlated with early relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important to categorize any residual radiographic abnormalities after initial treatment to distinguish complete remission from partial remission and prevent unnecessary toxic therapy. Diagnosis of recurrence is generally made with biopsy of a mass, and clinical staging is performed for prognosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical judgment often determines whether or not relapse should be documented by biopsy, but it is sound practice to obtain a tissue diagnosis. This is especially true in the setting of late relapse, since there is significant risk for second cancers (non-Hodgkin lymphoma or solid tumors) in these patients. In an instructive report, three young patients with Hodgkin lymphoma and gallium-avid nodal enlargement at 2.5 to 3 years posttreatment were found to have benign sarcoid-like lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35242?source=see_link\">",
"     \"Second malignancies after treatment of classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There may be some exceptions to this general rule. Early recurrence in the setting of incomplete remission, especially with persistence of constitutional symptoms or measurable radiographic abnormalities, may not demand a repeat biopsy. If, however, the disease has been unusually resistant to therapy, a biopsy may be warranted to confirm the initial diagnosis of Hodgkin lymphoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In all cases, clinical restaging is recommended at the time of relapse, especially if there appears to be an isolated relapse. Since most patients will receive systemic or combined modality therapy for relapse, the restaging has more prognostic than therapeutic importance.",
"   </p>",
"   <p>",
"    A number of restaging schemes have been proposed for relapsed Hodgkin lymphoma. The most straightforward simply employs the Ann Arbor staging system criteria to the extent of disease identified at the time of relapse and substitutes the letters RS (relapse stage) for CS (clinical stage) or PS (pathological stage) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/3,27\">",
"     3,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Positron emission tomography (PET) with fluorine-18 2-deoxyglucose (FDG) has been evaluated as an aid to clinical staging at diagnosis or relapse. In one study, FDG PET scanning revealed different extranodal manifestations compared with other procedures (CT scan, x-ray or ultrasonography) in 5 of 20 patients and established different clinical staging in three [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a second study of residual masses posttreatment in 13 patients with Hodgkin lymphoma and 11 patients with non-Hodgkin lymphoma, relapse was noted in 100 percent of patients in whom FDG PET was positive, irrespective of whether CT scanning was positive (four cases) or negative (one case) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/29\">",
"     29",
"    </a>",
"    ]. In contrast, for patients who were FDG PET negative, relapse occurred in 29 and 10 percent of those who were CT positive or negative, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30007?source=see_link&amp;anchor=H10#H10\">",
"     \"Monitoring of the patient with classical Hodgkin lymphoma during and after treatment\", section on 'PET/CT scan'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical experience indicates that residual abnormalities on computed tomographic scans that persist after treatment of large lymph node masses with radiation therapy (with or without chemotherapy), especially in the mediastinum, may be due to residual fibrosis and necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/30\">",
"     30",
"    </a>",
"    ]. Thus, some of these cases may represent a complete remission (called complete remission unconfirmed, CRu). A detailed discussion on the use of radiographic studies in HL is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30007?source=see_link\">",
"     \"Monitoring of the patient with classical Hodgkin lymphoma during and after treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic treatment is indicated in almost all patients with relapse after radiotherapy alone. These patients generally do as well or better with salvage combination chemotherapy as patients with advanced disease who have never received radiation, with a 10-year survival of nearly 90 percent in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/6\">",
"     6",
"    </a>",
"    ]. Whether or not adjunctive radiotherapy is associated with improved response is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the published experience of combination chemotherapy for salvage therapy in patients originally treated with radiation therapy has utilized MOPP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/57/40853?source=see_link\">",
"     mechlorethamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ). Current evidence, however, suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    based regimens are highly effective and probably superior to MOPP in the treatment of advanced stage Hodgkin lymphoma as initial agents and at relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Whether this advantage is seen in early stage patients who relapse after radiation therapy alone is not known, although one study did not demonstrate a significant difference between the two regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/6\">",
"     6",
"    </a>",
"    ]. ABVD has less toxicity and should be used as the standard regimen for patients who relapse after radiation therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=see_link\">",
"     \"Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The German Hodgkin Study Group (GHSG) has demonstrated that",
"    <span class=\"nowrap\">",
"     COPP/ABVD",
"    </span>",
"    or BEACOPP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , plus COPP), a more intensive regimen, can result in a failure from second relapse of 81 percent and overall survival of 89 percent in a series of 107 patients who relapse from extended field irradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/34\">",
"     34",
"    </a>",
"    ]. Independent negative prognostic factors for survival were B symptoms and extranodal involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Adjunctive radiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for the use of adjunctive radiotherapy in the management of patients with relapse after radiotherapy is to minimize the risk of relapse with chemotherapy alone. This is the same rationale used for primary treatment with chemotherapy. There is, for example, a 30 to 50 percent risk of early relapse in sites of bulk disease after initial treatment with chemotherapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. For this reason, many investigators include adjuvant radiotherapy when using primary chemotherapy for advanced Hodgkin lymphoma.",
"   </p>",
"   <p>",
"    Several prospective randomized trials have shown a disease-free survival advantage for combined modality therapy compared with chemotherapy alone in patients with advanced stage disease, but all have failed to show (with one exception) an overall survival advantage for adjunctive low-dose (20 Gy) radiation therapy. A meta-analysis of randomized trials confirmed the lack of a survival benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/38\">",
"     38",
"    </a>",
"    ]. As suggested by the meta-analysis, the reduction in mortality from Hodgkin lymphoma by the use of adjuvant radiation therapy may be balanced by increased mortality from causes other than Hodgkin lymphoma secondary to the more aggressive treatment. Nevertheless, improved disease-free survival is an important benefit in terms of ability to work and quality of life.",
"   </p>",
"   <p>",
"    The combined approach has been studied in the salvage setting following relapse after primary radiotherapy for localized disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/3,23\">",
"     3,23",
"    </a>",
"    ]. In one series, 109 patients who relapsed after initial radiation therapy alone received salvage treatment with chemotherapy alone or combined modality therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients with relapsed stage II to IV disease had a 10-year freedom from second relapse of 62 percent after combined modality therapy compared with only 37 percent after treatment with chemotherapy alone. Multivariate analysis showed that type of treatment for relapse was the most important predictor of outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several series have examined the outcome of patients treated for relapse after primary radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/2-5,39\">",
"     2-5,39",
"    </a>",
"    ]. The relapse rates after radiotherapy varied from 19 to 35 percent, the highest rates being in those series that included only clinical rather than laparotomy staging. The majority of patients in these series had salvage treatment based on MOPP chemotherapy or similar regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/40\">",
"     40",
"    </a>",
"    ]. The range of 10-year survivals following salvage chemotherapy was 57 to 71 percent.",
"   </p>",
"   <p>",
"    The important factors predicting outcome included age at presentation, extent of disease at relapse, and histologic subtype.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age &mdash; The International Database for Hodgkin lymphoma found a worse prognosis for patients older than 40 years of age (",
"      <a class=\"graphic graphic_figure graphicRef53846 \" href=\"UTD.htm?25/28/26061\">",
"       figure 2",
"      </a>",
"      ), patients whose relapse included an extranodal site, and those whose relapse was exclusively extranodal (stage IV) (",
"      <a class=\"graphic graphic_figure graphicRef70367 \" href=\"UTD.htm?30/30/31213\">",
"       figure 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Relapse stage &mdash; In one study, the clinical relapse stage (RS) was the most important prognostic factor followed by age over 50 years [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/3\">",
"       3",
"      </a>",
"      ]. The 10-year relapse-free survival was 88 percent in RS IA, 58 percent in RS IIA or IIIA, and 34 percent in RS I-IIIB or RS IV.",
"     </li>",
"     <li>",
"      Histology &mdash; A number of studies have found a better prognosis for patients with nodular sclerosis or nodular lymphocyte predominant histologies compared with the mixed cellularity or lymphocyte depletion type [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/2,4,5,41\">",
"       2,4,5,41",
"      </a>",
"      ]. In one study, for example, histologic type was the single most important prognostic factor for second complete remission (CR) and survival [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/2\">",
"       2",
"      </a>",
"      ]. Patients with nodular sclerosis or nodular lymphocyte predominant histologic type had higher rates of second CR (91 versus 66 percent) and 10-year survival (75 versus 43 percent) compared with mixed cellularity or lymphocyte depletion histologic type.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The length of disease-free duration prior to relapse has generally not been an important prognostic factor for outcome following relapse after radiotherapy. In one series, for example, patients with a disease-free interval less than one year had a 10-year cause-specific survival of 62 percent, compared with 65 percent in 197 patients with a disease-free interval between one and three years and 58 percent in 125 patients with a disease-free interval more than three years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/5\">",
"     5",
"    </a>",
"    ]. This is in contrast to the adverse impact of a short time to relapse in patients relapsing after chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/5,8\">",
"     5,8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=see_link\">",
"     \"Staging and prognosis of Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The overall survival of patients following relapse is similar to the results of primary treatment with MOPP in patients presenting with more advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/42\">",
"     42",
"    </a>",
"    ]. This suggests that prior radiotherapy does not cause drug resistance or a clinically significant compromise of chemotherapy dose intensity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7784/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Second recurrence or resistant disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients initially treated with radiotherapy who relapse after attaining a second complete remission as well as patients with resistant disease after first relapse may be candidates for high dose chemotherapy and bone marrow transplantation, or for second or third line chemotherapeutic agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21274?source=see_link\">",
"     \"Hematopoietic cell transplantation in classical Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38009?source=see_link\">",
"     \"Second and third line chemotherapy regimens and biologic therapy for relapsing or resistant classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3561952\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The use of radiation therapy without chemotherapy used to be a standard treatment option for patients with early stage Hodgkin lymphoma. Approximately 20 to 35 percent of patients with early stage Hodgkin lymphoma treated with radiation therapy alone relapse. Most relapses occur within the first three years after diagnosis, but 10 to 25 percent of patients will relapse after this time. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Presentation and detection of relapse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most recurrences present with symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a mass lesion detected on physical examination. Disease is typically limited to nodal sites located outside of the radiation field. Asymptomatic relapses and extranodal relapses are less common. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Presentation and detection of relapse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical factors at initial diagnosis which predict outcome after radiotherapy for early stage Hodgkin lymphoma include bulky disease, radiation field size, and stage of disease at diagnosis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Prognostic factors for relapse'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If disease recurrence is suspected, biopsy should be performed to confirm relapse and the patient should undergo a staging evaluation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with relapsed Hodgkin lymphoma after initial radiotherapy should be treated with chemotherapy. The sensitivity to chemotherapy is similar at the time of initial therapy and at the time of relapse, and salvage chemotherapy can achieve durable responses and remissions in approximately 70 percent of these patients. Whether or not adjunctive radiotherapy is associated with improved response is not known. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/1\">",
"      Oza AM, Ganesan TS, Leahy M, et al. Patterns of survival in patients with Hodgkin's disease: long follow up in a single centre. Ann Oncol 1993; 4:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/2\">",
"      Healey EA, Tarbell NJ, Kalish LA, et al. Prognostic factors for patients with Hodgkin disease in first relapse. Cancer 1993; 71:2613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/3\">",
"      Roach M 3rd, Brophy N, Cox R, et al. Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease. J Clin Oncol 1990; 8:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/4\">",
"      Specht L. Prognostic Factors in Hodgkin's Disease. Semin Radiat Oncol 1996; 6:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/5\">",
"      Horwich A, Specht L, Ashley S. Survival analysis of patients with clinical stages I or II Hodgkin's disease who have relapsed after initial treatment with radiotherapy alone. Eur J Cancer 1997; 33:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/6\">",
"      Ng AK, Li S, Neuberg D, et al. Comparison of MOPP versus ABVD as salvage therapy in patients who relapse after radiation therapy alone for Hodgkin's disease. Ann Oncol 2004; 15:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/7\">",
"      Specht L, Gray RG, Clarke MJ, Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. J Clin Oncol 1998; 16:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/8\">",
"      Garcia-Carbonero R, Paz-Ares L, Arcediano A, et al. Favorable prognosis after late relapse of Hodgkin's disease. Cancer 1998; 83:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/9\">",
"      Duchesne G, Crow J, Ashley S, et al. Changing patterns of relapse in Hodgkin's disease. Br J Cancer 1989; 60:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/10\">",
"      Herman TS, Hoppe RT, Donaldson SS, et al. Late relapse among patients treated for Hodgkin's disease. Ann Intern Med 1985; 102:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/11\">",
"      Bodis S, Henry-Amar M, Bosq J, et al. Late relapse in early-stage Hodgkin's disease patients enrolled on European Organization for Research and Treatment of Cancer protocols. J Clin Oncol 1993; 11:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/12\">",
"      Torrey MJ, Poen JC, Hoppe RT. Detection of relapse in early-stage Hodgkin's disease: role of routine follow-up studies. J Clin Oncol 1997; 15:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/13\">",
"      Guadagnolo BA, Punglia RS, Kuntz KM, et al. Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. J Clin Oncol 2006; 24:4116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/14\">",
"      Gilbert R. Radiotherapy in Hodgkin's disease (malignant granulomatosis): Anatomic and clinical foundations; governing principles; results. Am J Roentgenol 1939; 41:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/15\">",
"      Hanks GE, Kinzie JJ, White RL, et al. Patterns of care outcome studies. Results of the national practice in Hodgkin's disease. Cancer 1983; 51:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/16\">",
"      Kinzie JJ, Hanks GE, MacLean CJ, Kramer S. Patterns of care study: Hodgkin's disease relapse rates and adequacy of portals. Cancer 1983; 52:2223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/17\">",
"      Specht L. Tumour burden as the main indicator of prognosis in Hodgkin's disease. Eur J Cancer 1992; 28A:1982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/18\">",
"      Hellman S, Mauch P. Role of radiation therapy in the treatment of Hodgkin's disease. Cancer Treat Rep 1982; 66:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/19\">",
"      Hoppe RT, Coleman CN, Cox RS, et al. The management of stage I--II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience. Blood 1982; 59:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/20\">",
"      Verger E, Easton D, Brada M, et al. Radiotherapy results in laparotomy-staged Hodgkin's disease. Clin Radiol 1988; 39:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/21\">",
"      Tubiana M, Henry-Amar M, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood 1989; 73:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/22\">",
"      Mauch PM, Canellos GP, Shulman LN, et al. Mantle irradiation alone for selected patients with laparotomy-staged IA to IIA Hodgkin's disease: preliminary results of a prospective trial. J Clin Oncol 1995; 13:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/23\">",
"      Hoppe RT. The management of Hodgkin's disease in relapse after primary radiation therapy. Eur J Cancer 1992; 28A:1920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/24\">",
"      Mauch P, Henry-Amar M. International Database on Hodgkin's Disease: a cooperative effort to determine treatment outcome. Ann Oncol 1992; 3 Suppl 4:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/25\">",
"      Henry-Amar M, Friedman S, Hayat M, et al. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group. Ann Intern Med 1991; 114:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/26\">",
"      Epelbaum R, Ben-Arie Y, Bar-Shalom R, et al. Benign proliferative lesions mimicking recurrence of Hodgkin's disease. Med Pediatr Oncol 1997; 28:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/27\">",
"      Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/28\">",
"      Wiedmann E, Baican B, Hertel A, et al. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. Leuk Lymphoma 1999; 34:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/29\">",
"      Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/30\">",
"      Devizzi L, Maffioli L, Bonfante V, et al. Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease. Ann Oncol 1997; 8 Suppl 1:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/31\">",
"      Santoro A, Viviani S, Villarreal CJ, et al. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP. Cancer Treat Rep 1986; 70:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/32\">",
"      Connors JM, Klimo P, Adams G, et al. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol 1997; 15:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/33\">",
"      Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/34\">",
"      R&uuml;ffer JU, Ballova V, Glossmann J, et al. BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group. Leuk Lymphoma 2005; 46:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/35\">",
"      Cimino G, Biti GP, Cartoni C, Magrini SM. Chemotherapy versus radiotherapy in early-stage Hodgkin's disease: evidence of a more difficult rescue for patients relapsed after chemotherapy. Eur J Cancer 1992; 28A:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/36\">",
"      Yahalom J, Ryu J, Straus DJ, et al. Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combinations. J Clin Oncol 1991; 9:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/37\">",
"      Young RC, Canellos GP, Chabner BA, et al. Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy. Cancer 1978; 42:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/38\">",
"      Loeffler M, Brosteanu O, Hasenclever D, et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol 1998; 16:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/39\">",
"      Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002; 20:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/40\">",
"      Olver IN, Wolf MM, Cruickshank D, et al. Nitrogen mustard, vincristine, procarbazine, and prednisolone for relapse after radiation in Hodgkin's disease. An analysis of long-term follow-up. Cancer 1988; 62:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/41\">",
"      Wirth A, Chao M, Corry J, et al. Mantle irradiation alone for clinical stage I-II Hodgkin's disease: long-term follow-up and analysis of prognostic factors in 261 patients. J Clin Oncol 1999; 17:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7784/abstract/42\">",
"      Longo DL, Young RC, Wesley M, et al. Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 1986; 4:1295.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4763 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-81EFD22CC2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_38_7784=[""].join("\n");
var outline_f7_38_7784=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3561952\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRESENTATION AND DETECTION OF RELAPSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Detection of relapse",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sites of relapse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - In-field relapse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Site of relapse outside the radiation field",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Late relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PROGNOSTIC FACTORS FOR RELAPSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Radiation field",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Stage of disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Adjunctive radiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Second recurrence or resistant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3561952\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4763\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4763|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/10/23726\" title=\"figure 1\">",
"      RT alone or with chemo early HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/28/26061\" title=\"figure 2\">",
"      Age and mortality relapsed HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/30/31213\" title=\"figure 3\">",
"      Survival after relapse RT HL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4763|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/6/27756\" title=\"table 1\">",
"      Radiation fields in HL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/1/33821\" title=\"table 2\">",
"      Predictors DFS RT stage I-II HL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21274?source=related_link\">",
"      Hematopoietic cell transplantation in classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39786?source=related_link\">",
"      Initial treatment of advanced (stage III-IV) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3079?source=related_link\">",
"      Long-term follow-up of the patient with classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/19/30007?source=related_link\">",
"      Monitoring of the patient with classical Hodgkin lymphoma during and after treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38009?source=related_link\">",
"      Second and third line chemotherapy regimens and biologic therapy for relapsing or resistant classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35242?source=related_link\">",
"      Second malignancies after treatment of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/37/14935?source=related_link\">",
"      Staging and prognosis of Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11770?source=related_link\">",
"      Treatment of favorable prognosis early (stage I-II) classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34520?source=related_link\">",
"      Treatment of nodular lymphocyte-predominant Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/17/37145?source=related_link\">",
"      Treatment of relapse of classical Hodgkin lymphoma after initial chemotherapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_38_7785="Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease";
var content_f7_38_7785=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/38/7785/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/38/7785/contributors\">",
"     Michael A Becker, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/38/7785/contributors\">",
"     Lawrence M Ryan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/38/7785/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/38/7785/contributors\">",
"     H Ralph Schumacher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/38/7785/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/38/7785/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/38/7785/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precipitation of crystals of calcium pyrophosphate dihydrate (CPPD) in connective tissues may be asymptomatic or may be associated with several clinical syndromes. These disorders, including an acute and chronic inflammatory arthropathy and radiographic calcification, comprise the spectrum of calcium pyrophosphate crystal deposition disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of CPPD crystal deposition disease are discussed here. The pathogenesis and etiology of this disorder, as well as the treatment of CPPD deposition diseases including pseudogout, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6375?source=see_link\">",
"     \"Pathogenesis and etiology of calcium pyrophosphate crystal deposition disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18134?source=see_link\">",
"     \"Treatment of calcium pyrophosphate crystal deposition disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272267074\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The names traditionally used for CPPD crystal deposition diseases include pseudogout, chondrocalcinosis, and pyrophosphate arthropathy. A European League Against Rheumatism (EULAR) consensus panel has suggested alternative terminology and has reviewed diagnostic approaches to these conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/4\">",
"     4",
"    </a>",
"    ]. The clinical syndromes, findings, and limitations of these terms, together with the nomenclature proposed by EULAR, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pseudogout &mdash; Pseudogout accurately describes acute attacks of CPPD crystal-induced synovitis, which clinically resemble urate gout. However, the majority of individuals with CPPD crystal deposition never experience such episodes. The EULAR consensus panel prefers the term &ldquo;acute calcium pyrophosphate (CPP) crystal arthritis&rdquo; instead of pseudogout.",
"     </li>",
"     <li>",
"      Chondrocalcinosis &mdash; Chondrocalcinosis refers to radiographic calcification in hyaline",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fibrocartilage (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef54821 \" href=\"UTD.htm?0/12/207\">",
"       image 1",
"      </a>",
"      ). It is commonly present in patients with CPPD crystal deposition disease but is neither absolutely specific for CPPD nor universal among affected patients. The EULAR group designates this finding as &ldquo;cartilage calcification (CC).&rdquo;",
"     </li>",
"     <li>",
"      Pyrophosphate arthropathy &mdash; Pyrophosphate arthropathy is the term sometimes used for the joint disease or radiographic abnormalities accompanying CPPD crystal deposition. Although this name has little justification in terms of the pathologic anatomy of the disorder, evidence of aberrant inorganic pyrophosphate metabolism in the pathogenesis of CPPD crystal deposition disease may legitimize use of this term.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The term &ldquo;calcium pyrophosphate deposition&rdquo; (also abbreviated as CPPD) is proposed by the EULAR task force as the umbrella term for all instances of calcium pyrophosphate crystal occurrence.",
"   </p>",
"   <p>",
"    The EULAR consensus panel has rigorously reviewed the literature regarding CPPD crystal deposition, has proposed changes in nomenclature, and has summarized levels of evidence regarding diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/4\">",
"     4",
"    </a>",
"    ]. A commentary has been published concerning the EULAR committee recommendations, which is co-authored by one of the authors of this topic review, that generally supports use of the 2011 EULAR terms [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/5\">",
"     5",
"    </a>",
"    ]. However, these terms are not widely accepted, and we have, therefore, retained use of the traditional terminology while providing the proposed terms in parentheses following the traditional names for these conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical classification of CPPD crystal deposition disease has emerged from the studies of McCarty [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/1\">",
"     1",
"    </a>",
"    ] and colleagues [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This classification draws particular attention to the capacity of this disorder to mimic virtually any type of arthritis. The clinical spectrum of CPPD crystal deposition disease and the nomenclature (in parentheses) proposed by the European League Against Rheumatism include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Asymptomatic disease (&ldquo;asymptomatic CPPD&rdquo;)",
"     </li>",
"     <li>",
"      Pseudogout (&ldquo;acute CPP crystal arthritis&rdquo;)",
"     </li>",
"     <li>",
"      Pseudo-rheumatoid arthritis (&ldquo;chronic CPP crystal inflammatory arthritis&rdquo;)",
"     </li>",
"     <li>",
"      Pseudo-osteoarthritis, with or without superimposed acute attacks (&ldquo;osteoarthritis [OA] with CPPD&rdquo;)",
"     </li>",
"     <li>",
"      Pseudo-neuropathic joint disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The majority of individuals with CPPD crystal deposition disease are probably asymptomatic with respect to joint involvement. Among those who develop symptoms, there is considerable diversity in the patterns of joint disease. The clinical manifestations of pseudogout, pseudo-rheumatoid arthritis, pseudo-osteoarthritis, and pseudo-neuropathic joint disease closely mimic those of gout, rheumatoid arthritis, osteoarthritis, and neuropathic joint disease, respectively, thereby making an accurate diagnosis challenging. The following discussion will review the manifestations of CPPD crystal deposition disease with an emphasis upon features which help distinguish these diseases from related disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Asymptomatic CPPD crystal deposition (\"asymptomatic CPPD\")",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most joints in which CPPD crystal deposition is readily apparent on radiographs are asymptomatic. This statement appears valid even among those in whom acute or chronic clinical manifestations of CPPD crystal deposition in one or several joints have occurred. However, patients with apparently asymptomatic disease may have manifestations of an arthritic disorder upon close questioning. As an example, in one series of older patients with ostensibly asymptomatic (lanthanic) CPPD crystal deposition, a higher frequency of wrist complaints and genu varus deformity was reported by questionnaire and was detected by examination, respectively, than in a control group of similar age but without radiographic chondrocalcinosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pseudogout (\"acute CPP crystal arthritis\")",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudogout is characterized by self-limited acute or subacute attacks of arthritis involving only one or several extremity joints (monoarthritis and pauci[oligo]-arthritis, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/7\">",
"     7",
"    </a>",
"    ]. These attacks closely resemble those of urate gout both in the typical accompanying signs of severe acute inflammation and in the occasional occurrence of cluster attacks or, conversely, petite attacks (which are minimally painful episodes of joint warmth and swelling). Trauma, surgery, or severe medical illness frequently provokes acute attacks in both of these crystal-induced arthritides. Flares of pseudogout after parathyroidectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/8\">",
"     8",
"    </a>",
"    ] have been particularly noted and may reflect abrupt reduction in serum calcium levels during postoperative hypoparathyroidism. Such reduction may cause partial dissolution of crystals with subsequent release from matrix into the joint fluid, allowing phagocytosis and the phlogistic response of inflammatory cells. Intraarticular hyaluronate injection or treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    or GM-CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/9-11\">",
"     9-11",
"    </a>",
"    ] has been reported to precipitate acute attacks of pseudogout. Rarely, masses of CPPD crystals resembling gouty tophi accumulate in synovium and adjacent joint structure, and lead to locally destructive and compressive symptoms.",
"   </p>",
"   <p>",
"    Despite these similarities, the joints most commonly involved in an acute episode differ between gout and pseudogout. The knee is affected in over 50 percent of all acute attacks of pseudogout, whereas the first metatarsophalangeal joint is more frequently involved in gout. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=see_link\">",
"     \"Clinical manifestations and diagnosis of gout\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, differences in the patterns of joint involvement in urate gout and pseudogout are",
"    <strong>",
"     insufficient",
"    </strong>",
"    to permit definite diagnosis without demonstration of the specific crystal in the inflammatory joint effusion (",
"    <a class=\"graphic graphic_picture graphicRef55730 \" href=\"UTD.htm?37/5/37981\">",
"     picture 1",
"    </a>",
"    ). Furthermore, coexistence of urate and CPPD crystals in a single inflammatory effusion is neither uncommon nor unexpected, given the observed frequencies of hyperuricemia (20 percent) and gout (5 percent) among patients with CPPD crystal deposition disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Synovial fluid'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Systemic findings such as fever, leukocytosis with a left shift in the differential count, and an elevated sedimentation rate can occur during acute attacks of pseudogout, although the frequency is probably less than in acute gouty arthritis. In some cases, the systemic features are quite prominent and may suggest pyogenic arthritis, osteomyelitis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    systemic sepsis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pseudo-rheumatoid arthritis (\"chronic CPP crystal inflammatory arthritis\")",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term pseudo-rheumatoid arthritis applies to a nonerosive, asynchronous, inflammatory arthritis in which CPPD crystals are demonstrable in joint fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/2\">",
"     2",
"    </a>",
"    ]. It occurs in 5 percent or less of patients with symptomatic CPPD crystal deposition disease.",
"   </p>",
"   <p>",
"    Among patients with pseudo-rheumatoid arthritis, multiple joints are involved with attacks of articular inflammation lasting up to several months. The clinical picture may closely resemble that of rheumatoid arthritis, with significant morning stiffness, fatigue, synovial thickening, localized edema, and restricted joint motion due either to active inflammation or to flexion contracture.",
"   </p>",
"   <p>",
"    Radiographic changes are more typical of osteoarthritis than of rheumatoid arthritis despite the pattern of clinical joint involvement suggestive of the latter disorder. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Imaging'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Unlike gout, which is negatively associated with rheumatoid arthritis, CPPD crystal deposition disease and rheumatoid arthritis appear to coexist about as frequently as would be expected from the individual prevalence of the two disorders. It is important to distinguish between the coexistence of rheumatoid arthritis and CPPD crystal deposition disease and the expression of one masquerading as the other, because management approaches substantially differ in the two circumstances.",
"   </p>",
"   <p>",
"    A rare subtype of pseudo-rheumatoid arthritis is characterized by prominent systemic features such as leukocytosis, fever, mental confusion, and inflammatory polyarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/12\">",
"     12",
"    </a>",
"    ]. If this clinical presentation occurs in older adults, it can closely mimic systemic sepsis, from which it is distinguishable both by the presence of CPPD crystals in synovial fluid from affected joints and by reversal of the clinical features during antiinflammatory drug treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pseudo-osteoarthritis (\"OA with CPPD\")",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 50 percent of patients with symptomatic CPPD crystal deposition disease show progressive joint degeneration, usually involving multiple joints. In about one-half of such patients, episodes of acute inflammatory arthritis typical of pseudogout punctuate the course. In the remainder, joint degeneration proceeds by a process more typical of classical osteoarthritis.",
"   </p>",
"   <p>",
"    When the arthritic process occurs in joints typical for osteoarthritis (such as the interphalangeal joints of the hands, the first carpometacarpal joints, the knees, or the bunion joints), even x-ray or joint fluid evidence of CPPD crystal deposition does not permit an unequivocal diagnosis. However, an etiologic or accelerating role for CPPD crystal deposition in joint degeneration seems reasonable when radiographic calcification is present early in the course of degeneration, particularly if the degenerative changes also involve joints atypical for osteoarthritis (wrists, metacarpophalangeal joints, elbows, and shoulders) in the absence of a preceding history of joint trauma or of vocational or avocational stress.",
"   </p>",
"   <p>",
"    The most commonly affected joints in pseudo-osteoarthritis are the knees, followed by the wrists, metacarpophalangeal joints, hips, shoulders, elbows, and spine. Although a symmetric pattern of joint involvement is frequent, unilateral or more severe degenerative change on one side is not unusual.",
"   </p>",
"   <p>",
"    Findings on clinical examination of individual joints do not typically differ from those observed in osteoarthritis. In addition to the atypical distribution, other features on examination which should alert the clinician to possible CPPD crystal deposition disease include contractures of involved joints and valgus deformities of the knees.",
"   </p>",
"   <p>",
"    With cartilage loss during the course of progressive joint degeneration, previously apparent chondrocalcinosis may become increasingly difficult or impossible to detect, thereby obscuring the diagnosis. The radiographic features of CPPD crystal deposition which may aid in discriminating between these two disorders are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pseudo-neuropathic joint disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropathic arthropathy is characterized by severe joint degeneration and disruption occurring in the course of neurologic disorders leading to joint denervation. The affected joint is called a Charcot joint. Underlying disorders include diabetes mellitus (most common), tabes dorsalis, and syringomyelia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39527?source=see_link\">",
"     \"Diabetic neuropathic arthropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of reports have documented CPPD crystal deposition in association with severe joint degeneration which closely resembles neuropathic arthropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. An underlying neurologic impairment (typically tabes) has been demonstrated in some cases [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In contrast, neurologic function is normal in pseudo-neuropathic joint disease. The term &ldquo;pseudo-neuropathic&rdquo; also implies that, when crystal deposition is associated with certain neurologic deficits, the presence of crystals serves to amplify the destructive consequences of joint denervation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Spinal involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;CPPD crystal deposition in and about the spine has been associated with a number of clinical manifestations. Spine stiffness, sometimes associated with bony ankylosis, can resemble that of ankylosing spondylitis or diffuse idiopathic skeletal hyperostosis (DISH). Such symptoms have been most commonly encountered in familial CPPD crystal deposition disease. In addition, crystal deposition in the ligamentum flavum at the cervical spine level or in the posterior longitudinal ligament at lower levels of the spine may lead to spinal cord compression syndromes or to symptoms either of acute nerve compression or of chronic spinal stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;CPPD crystal deposition occurring in the wake of trauma or prior surgery may result in localized inflammation or degeneration, most commonly in the knee or in the lower or lumbar spine. In addition, CPPD crystal deposition in bursae, ligaments, and tendons may be sufficient to cause local nerve compression, as in the carpal tunnel [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SYNOVIAL FINDINGS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Synovial fluid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most salient finding on synovial fluid analysis in CPPD crystal deposition disease is the presence of positively birefringent CPPD crystals by compensated polarized light microscopy. In inflamed joints during an attack of pseudogout, phagocytosed crystals within polymorphonuclear leukocytes are virtually always present (",
"    <a class=\"graphic graphic_picture graphicRef55730 \" href=\"UTD.htm?37/5/37981\">",
"     picture 1",
"    </a>",
"    ). In addition, the total synovial fluid leukocyte concentration is typically 15,000 to 30,000 per mm",
"    <sup>",
"     3",
"    </sup>",
"    , 90 percent of which are neutrophils. The findings are somewhat different in chronically symptomatic joints in which the crystals are often found extracellularly.",
"   </p>",
"   <p>",
"    The abundance of CPPD crystals in the synovial fluid is generally related to the degree of clinically apparent inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/2\">",
"     2",
"    </a>",
"    ]; however, large discrepancies between these variables can occur. The proportion of intracellular crystals varies roughly with the level of inflammation (as reflected clinically and by the synovial fluid neutrophil concentration).",
"   </p>",
"   <p>",
"    In contrast to the negatively birefringent monosodium urate crystals in acute gouty arthritis (",
"    <a class=\"graphic graphic_picture graphicRef74417 \" href=\"UTD.htm?36/26/37282\">",
"     picture 2",
"    </a>",
"    ), CPPD crystals are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      More difficult to detect",
"     </li>",
"     <li>",
"      Smaller",
"     </li>",
"     <li>",
"      Only weakly (positively) or not birefringent",
"     </li>",
"     <li>",
"      More polymorphic",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some instances, for example, CPPD crystals are smaller than can be resolved even by 1000-fold magnification with the aid of phase contrast microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examination of synovial fluid for CPPD crystals should be carried out promptly after joint aspiration, because successful identification of the crystals diminishes as the time elapsed between joint aspiration and microscopic examination increases. Another technical source of error is that positively birefringent material other than CPPD crystals may be identified in joint fluid samples unless care is taken to clean and remove dust from the microscope slide and cover slip. Lack of attention to these details may contribute to reports of a relatively low specificity and sensitivity in identifying CPPD crystals in synovial fluid, particularly when the observers carrying out the analysis are relatively inexperienced [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. The European League Against Rheumatism recommendations for CPPD suggest refinement of an optimal protocol (including training) and standards for identification of CPPD crystals in joint fluids [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Synovial tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tissue sections may also be examined for CPPD crystals. Sections stained with hematoxylin and eosin (H&amp;E) are less likely to demonstrate typical birefringent crystals, possibly due to the dissolution of crystalline CPPD in the acid reagents. Use of alizarin red better preserves the crystals and reduces the likelihood of a false negative result, but false positive staining may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/23\">",
"     23",
"    </a>",
"    ]. A nonaqueous stain, such as Wright&rsquo;s, is another alternative to routine H&amp;E staining for synovial tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging evidence for CPPD deposition has traditionally relied upon plain film radiography. Ultrasonographic findings that correlate with radiographic features of CPPD disease have also been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Plain film radiography",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Chondrocalcinosis (\"cartilage calcification\")",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic evidence of calcium crystal deposition is the defining feature of chondrocalcinosis. CPPD crystal deposits typically appear as punctate and linear radiodensities in fibrocartilage, in hyaline or articular cartilage (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef54821 \" href=\"UTD.htm?0/12/207\">",
"     image 1",
"    </a>",
"    ), and, with lesser frequency, in ligaments and joint capsules. Although deposits of carbonate-substituted calcium phosphate crystals may occasionally cause confusion, such deposits are usually faint and are irregularly contoured.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cartilage &mdash; Among affected fibrocartilages in CPPD crystal deposition disease are the menisci of the knee (usually bilaterally), the symphysis pubis, the triangular discs of the distal radioulnar joint, and the glenoid and acetabular labra. CPPD crystal deposits in hyaline cartilage frequently appear as a radiopaque line paralleling the surface of the underlying bone.",
"     </li>",
"     <li>",
"      Joints &mdash; Larger joints, such as the knee, elbow, shoulder, and hip, are most frequently involved in CPPD crystal deposition disease, but almost any diarthrodial joint may be affected radiographically. Articular capsule or synovial calcification is most commonly detected in large joints, often appearing more faint and diffuse than the cartilage calcification (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef54821 \" href=\"UTD.htm?0/12/207\">",
"       image 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Calcification due to CPPD crystal deposition also can occur in bursae, ligaments, and tendons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Degenerative changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even in the absence of demonstrable chondrocalcinosis, CPPD crystal deposition is often associated with degenerative radiographic changes in joints. As noted above, CPPD crystal deposition disease should be considered when radiographic features of osteoarthritis occur in joints not commonly affected in primary osteoarthritis. The diagnosis is more difficult when the pattern of distribution of osteoarthritic changes is similar to that of typical osteoarthritis, unless cartilage calcification is apparent at the onset of degenerative changes or occurs earlier in life than usual and without a pertinent vocational or avocational history.",
"   </p>",
"   <p>",
"    Characteristic degenerative changes in CPPD crystal deposition disease include subchondral cysts, osteophyte formation, and bone and cartilage fragmentation. Stress fractures or osteonecrosis (avascular necrosis), particularly in the structures of the knee, may be consequences of or may be promoted by CPPD crystal deposition",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Other radiographic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of radiographic signs restricted to particular joints which are more or less characteristic of CPPD arthropathy have also been described. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Squared-off bone ends and hook-like osteophytes in the metacarpophalangeal (MCP) joints, particularly if these changes are located in the second and third MCP joints. Such changes are especially common in hemochromatosis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/24\">",
"       24",
"      </a>",
"      ] and hemochromatosis-associated CPPD [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=see_link\">",
"       \"Clinical manifestations of hereditary hemochromatosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Isolated or unusually extensive radiocarpal joint narrowing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      navicular-lunate dissociation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/26\">",
"       26",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Severe patellofemoral joint space degeneration, especially with a wrapped-around deformity of the patella on the femur. This finding is seen in hyperparathyroidism with or without CPPD crystal deposition.",
"     </li>",
"     <li>",
"      Notching or erosion of the distal femoral cortex superior to the patella [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/27\">",
"       27",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Axial skeleton changes, such as subchondral cysts in the small joints of the spine and sacroiliac joints, calcification of multiple intervertebral discs, and sacroiliac joint vacuum phenomena [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/28\">",
"       28",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Ultrasonographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following findings on ultrasonography of articular and fibrocartilage have been suggested to be indicative of the presence of deposits of CPPD crystals [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thin hyperechoic bands paralleling the articular cartilage surface",
"     </li>",
"     <li>",
"      Small punctate hyperechoic spots, referred to as a &ldquo;punctate pattern&rdquo; often with acoustic shadowing, most often found in images of fibrocartilage of the wrist and in tendons (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef66316 \" href=\"UTD.htm?0/41/660\">",
"       image 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nodular hyperechoic deposits in bursae",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The sensitivity and specificity of ultrasonography for CPPD crystal deposition disease needs to be further studied [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/4\">",
"     4",
"    </a>",
"    ]. However, based upon the limited data available, this imaging modality appears to have sensitivity for aspiration-confirmed CPPD disease that is similar to that of plain film radiography when employed by experts in joint imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/29\">",
"     29",
"    </a>",
"    ]. The utility of ultrasound in diagnosing cartilage calcification outside of research centers is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of CPPD crystal deposition disease should be suspected in the patient (most often over age 65) with acute or subacute attacks of arthritis (particularly of the knee), arthritis similar in character to rheumatoid arthritis or osteoarthritis, apparent CPPD crystal deposition on x-ray, or other less common presentations (as mentioned previously).",
"   </p>",
"   <p>",
"    Establishing the diagnosis of CPPD crystal deposition is largely based upon the demonstration of CPPD crystals in tissue or synovial fluid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    upon radiographic evidence of the disease. If possible, therefore, aspiration of an affected joint with synovial fluid analysis for CPPD crystals should be promptly undertaken. In addition, since the radiographic features of CPPD crystal deposition disease have sufficient specificity and sensitivity, we recommend screening radiographs of other frequently involved joints in all patients in whom the diagnosis is suspected and in whom x-rays of pertinent affected joints have not yielded a definitive diagnosis. With appropriate exposures and adequate film quality, a panel of radiographs consisting of an anterior to posterior (AP) view of each knee, an AP view of the symphysis pubis, and posterior to anterior (PA) views of each wrist should suffice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following diagnostic criteria and diagnostic classification for CPPD crystal deposition disease are based upon those initially proposed by McCarty and colleagues [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A definite diagnosis of CPPD crystal deposition disease requires either:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The demonstration of CPPD crystals in tissue or synovial fluid by definitive means (eg, x-ray diffraction, etc)",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      The presence of",
"      <strong>",
"       both",
"      </strong>",
"      positively (but weakly) birefringent crystals by compensated polarized light microscopy and typical cartilage or joint capsule calcification on x-ray examination",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In clinical practice, definitive demonstration of crystals by x-ray diffraction powder pattern, chemical analysis, or atomic force microscopy is only rarely achieved except in specialized centers of research. Thus, the diagnosis is most commonly established by fulfilling the combination of radiographic and synovial fluid analysis criteria.",
"   </p>",
"   <p>",
"    A probable diagnosis of CPPD crystal deposition disease occurs with either:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The identification of positively (but weakly) birefringent crystals by compensated polarized light microscopy",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      The presence of typical cartilage or joint capsule calcification on radiographic examination",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The majority of patients considered by rheumatologists to have CPPD crystal deposition disease most likely fall into the probable disease category. Given the state of management of this disorder, this fact does not appear to be a serious diagnostic quandary if alternative diagnostic possibilities are carefully considered and are acted upon appropriately.",
"   </p>",
"   <p>",
"    Fulfillment of either of the following criteria should raise the suspicion of",
"    <strong>",
"     possible",
"    </strong>",
"    CPPD crystal deposition disease and should prompt a direct evaluation aimed at fulfilling specific criteria for the disorder:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute arthritis of large joints, especially the knees,",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      Chronic arthritis which resembles osteoarthritis, particularly if the involved joints are not typical for osteoarthritis (wrists, MCP joints, elbows, and shoulders) and if it is accompanied by acute, self-limited attacks. As previously mentioned, distinction from osteoarthritis is further suggested by radiographic features typical of CPPD arthropathy in individual joints and the spine (even in the absence of chondrocalcinosis); severe and progressive joint degeneration, especially with prominent subchondral cyst formation; and tendon calcifications apparent on radiographs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The criteria for possible CPPD crystal deposition disease are aimed at calling attention to the possibility of the disorder and at stimulating the search for more definitive criteria. They are not intended to attach a diagnostic label to an individual patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Screening for associated diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a diagnosis of CPPD crystal deposition disease may also have one of a number of associated disorders, including hemochromatosis, hyperparathyroidism, hypomagnesemia, hypophosphatasia, hypothyroidism, and familial hypocalciuric hypercalcemia (",
"    <a class=\"graphic graphic_table graphicRef65287 \" href=\"UTD.htm?23/26/23979\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6375?source=see_link\">",
"     \"Pathogenesis and etiology of calcium pyrophosphate crystal deposition disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given these disease associations, we agree with the recommendation that patients diagnosed with CPPD crystal deposition undergo the following serum screening studies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Calcium",
"     </li>",
"     <li>",
"      Phosphorus",
"     </li>",
"     <li>",
"      Magnesium",
"     </li>",
"     <li>",
"      Alkaline phosphatase",
"     </li>",
"     <li>",
"      Ferritin",
"     </li>",
"     <li>",
"      Iron",
"     </li>",
"     <li>",
"      Transferrin",
"     </li>",
"     <li>",
"      Thyroid-stimulating hormone",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Appropriate further evaluation should be undertaken if one or more of these values are abnormal. In patients over 60 years of age, serum magnesium and alkaline phosphatase determinations may be omitted because chronic hypomagnesemia and hypophosphatasia present earlier in life. Despite the value of establishing the presence of one of these associated disorders in CPPD crystal deposition disease, the results of specific treatments directed at the respective associated disorders, such as reversal of the iron overload in hemochromatosis or of the parathyroid hormone excess in hyperparathyroidism, have been ineffective in halting or reversing the crystal deposition disorder.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of each of the presentations described above (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Clinical manifestations'",
"    </a>",
"    above) is addressed separately below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymptomatic CPPD deposition (&ldquo;asymptomatic CPPD&rdquo;) &mdash; Asymptomatic CPPD deposition is typically discovered when chondrocalcinosis is incidentally noted on radiographs. Articular or fibrocartilage calcification may be an indication of an underlying, potentially treatable disorder for which screening tests may be valuable. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Screening for associated diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pseudogout (&ldquo;acute CPP crystal arthritis&rdquo;) &mdash; The differential diagnosis of an acute monoarthritis is discussed in detail separately; however, infection, trauma, bleeding, and other crystal-associated diseases (eg, gout) are among the important disorders to consider. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28904?source=see_link\">",
"       \"Evaluation of the adult with monoarticular pain\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The presence of CPPD crystals in joint fluid does",
"      <strong>",
"       not",
"      </strong>",
"      exclude infection. Thus, Gram stain, as well as joint fluid and blood cultures, is generally necessary to exclude an infectious etiology.",
"     </li>",
"     <li>",
"      Pseudo-rheumatoid arthritis (&ldquo;chronic CPP inflammatory arthritis&rdquo;) &mdash; A chronic polyarticular presentation of CPPD deposition disease must be distinguished from other causes of polyarthralgia or polyarthritis. The diagnostic approach to adults with polyarticular joint pain is presented in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34039?source=see_link\">",
"       \"Evaluation of the adult with polyarticular pain\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Diagnostic confusion may arise when inflammation is more or less symmetrical and, particularly, when rheumatoid factor is detectable (as is the case in a substantial proportion of normal older individuals). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=see_link\">",
"       \"Diagnosis and differential diagnosis of rheumatoid arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pseudo-osteoarthritis (&ldquo;OA with CPPD&rdquo;) &mdash; Osteoarthritis with typical symptoms, physical findings, and radiographic features is the major disorder to consider when pseudo-osteoarthritis is being considered. The clinical manifestations and diagnosis of osteoarthritis are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12056?source=see_link\">",
"       \"Clinical manifestations of osteoarthritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=see_link\">",
"       \"Diagnosis and classification of osteoarthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pseudo-neuropathic joint disease &mdash; True neuropathic joint destruction is characterized by loss of joint position sensation and, sometimes, by loss of other sensory modalities, such as pain and temperature sensation. As mentioned earlier, disorders associated with neuropathic arthropathy (Charcot joint) include diabetes mellitus (most common), tabes dorsalis, syringomyelia, and spinal cord injuries.",
"     </li>",
"     <li>",
"      Nerve or spinal cord compression &mdash; Mass effects from collections of CPPD crystals and associated soft tissue must be distinguished from other calcifying or ossifying mass lesions. An intraspinal mass with punctate soft tissue calcification suggests chondrosarcoma, and histopathologic examination of the resected tissue may be required to exclude a malignant neoplasm [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7785/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=see_link&amp;anchor=H23#H23\">",
"       \"Spinal cord tumors\", section on 'Sarcomas'",
"      </a>",
"      .) Monosodium urate tophi may rarely cause neurologic compressive syndromes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=see_link\">",
"       \"Clinical manifestations and diagnosis of gout\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/9/10386?source=see_link\">",
"       \"Patient information: Pseudogout (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/15/34033?source=see_link\">",
"       \"Patient information: Pseudogout (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H81271603\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The names traditionally used for the calcium pyrophosphate crystal-related disorders include pseudogout, for the acute attacks caused by calcium pyrophosphate crystal deposition; chondrocalcinosis, for the radiographic calcification in hyaline",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fibrocartilage; and pyrophosphate arthropathy, for the radiographic or joint abnormalities accompanying calcium pyrophosphate dihydrate (CPPD) crystal deposition. (See",
"      <a class=\"local\" href=\"#H272267074\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical spectrum of CPPD crystal deposition disease is diverse, and the majority of patients are probably asymptomatic. The range of presentations, with alternative terms proposed by the European League Against Rheumatism noted parenthetically, includes (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H272267074\">",
"       'Terminology'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Asymptomatic disease (&ldquo;asymptomatic CPPD&rdquo;) (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Asymptomatic CPPD crystal deposition (\"asymptomatic CPPD\")'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Pseudogout (&ldquo;acute CPP crystal arthritis&rdquo;) (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Pseudogout (\"acute CPP crystal arthritis\")'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Pseudo-rheumatoid arthritis (&ldquo;chronic CPP crystal inflammatory arthritis&rdquo;) (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Pseudo-rheumatoid arthritis (\"chronic CPP crystal inflammatory arthritis\")'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Pseudo-osteoarthritis, with or without superimposed acute attacks (&ldquo;osteoarthritis with CPPD&rdquo;) (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Pseudo-osteoarthritis (\"OA with CPPD\")'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Pseudo-neuropathic joint disease (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Pseudo-neuropathic joint disease'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Synovial fluid analysis in CPPD crystal deposition disease is characterized by the presence of weakly positively birefringent CPPD crystals that may be detected by compensated polarized light microscopy. Phagocytosed crystals within polymorphonuclear leukocytes are virtually always present in inflamed joints during an acute attack of pseudogout (",
"      <a class=\"graphic graphic_picture graphicRef55730 \" href=\"UTD.htm?37/5/37981\">",
"       picture 1",
"      </a>",
"      ). Examination of synovial fluid for CPPD crystals should be carried out promptly after joint aspiration, because successful identification of the crystals diminishes as the time elapsed between joint aspiration and microscopic examination increases. The total synovial fluid leukocyte concentration is typically 15,000 to 30,000 per mm",
"      <sup>",
"       3",
"      </sup>",
"      , 90 percent of which are neutrophils. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Synovial findings'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Synovial fluid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plain film radiographic evidence of calcium crystal deposition is the defining feature of chondrocalcinosis. CPPD crystal deposits typically appear as punctate and linear radiodensities in fibrocartilage, in hyaline or articular cartilage (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef54821 \" href=\"UTD.htm?0/12/207\">",
"       image 1",
"      </a>",
"      ), and, with lesser frequency, in ligaments and joint capsules. Even in the absence of demonstrable chondrocalcinosis, CPPD crystal deposition is often associated with degenerative radiographic changes in joints. Ultrasonographic findings that correlate with radiographic features of CPPD disease have also been described (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef66316 \" href=\"UTD.htm?0/41/660\">",
"       image 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Imaging'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Plain film radiography'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Ultrasonographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A diagnosis of CPPD crystal deposition disease should be suspected in the patient (most often over age 65) with acute or subacute attacks of arthritis (particularly of the knee), arthritis similar in character to rheumatoid arthritis or osteoarthritis, apparent CPPD crystal deposition on x-ray, or other less common presentations. Establishing the diagnosis is largely based upon the demonstration of CPPD crystals in tissue or synovial fluid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      upon radiographic evidence of the disease. Screening radiographs of other frequently involved joints should be obtained in all patients in whom the diagnosis is suspected and in whom x-rays of pertinent affected joints have not yielded a definitive diagnosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Diagnostic criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with a diagnosis of CPPD crystal deposition disease may also have one of a number of associated disorders, including hemochromatosis, hyperparathyroidism, hypomagnesemia, hypophosphatasia, hypothyroidism, and familial hypocalciuric hypercalcemia (",
"      <a class=\"graphic graphic_table graphicRef65287 \" href=\"UTD.htm?23/26/23979\">",
"       table 1",
"      </a>",
"      ). Given these disease associations, patients diagnosed with CPPD crystal deposition should undergo the following serum screening studies: calcium, phosphorus, magnesium, alkaline phosphatase, ferritin, iron, transferrin, and thyroid-stimulating hormone. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Screening for associated diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of CPPD is broad and differs for each of the potential clinical presentations. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/1\">",
"      McCarty DJ. Calcium pyrophosphate dihydrate crystal deposition disease--1975. Arthritis Rheum 1976; 19 Suppl 3:275.",
"     </a>",
"    </li>",
"    <li>",
"     Rosenthal AK, Ryan LM, McCarty DJ. Calcium pyrophosphate crystal deposition disease, pseudogout, and articular chondrocalcinosis. In: Arthritis and Allied Conditions, 15th, Koopman WJ, Moreland LW (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.2373.",
"    </li>",
"    <li>",
"     Rosenthal AK. Pseudogout: Presentation, natural history, and associated conditions. In: Crystal-Induced Arthropathies: Gout, Pseudogout, and Apatite-Associated Syndromes, Wortmann RL, Schumacher HR Jr, Becker MA, Ryan LM (Eds), Taylor and Francis Group, New York 2006. p.99.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/4\">",
"      Zhang W, Doherty M, Bardin T, et al. European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis 2011; 70:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/5\">",
"      Rosenthal AK, Ryan LM. Crystal arthritis: calcium pyrophosphate deposition-nothing 'pseudo' about it! Nat Rev Rheumatol 2011; 7:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/6\">",
"      Ellman MH, Levin B. Chondrocalcinosis in elderly persons. Arthritis Rheum 1975; 18:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/7\">",
"      Dieppe PA, Alexander GJ, Jones HE, et al. Pyrophosphate arthropathy: a clinical and radiological study of 105 cases. Ann Rheum Dis 1982; 41:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/8\">",
"      Bilezikian JP, Connor TB, Aptekar R, et al. Pseudogout after parathyroidectomy. Lancet 1973; 1:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/9\">",
"      Luzar MJ, Altawil B. Pseudogout following intraarticular injection of sodium hyaluronate. Arthritis Rheum 1998; 41:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/10\">",
"      Malnick SD, Ariel-Ronen S, Evron E, Sthoeger ZM. Acute pseudogout as a complication of pamidronate. Ann Pharmacother 1997; 31:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/11\">",
"      Sandor V, Hassan R, Kohn E. Exacerbation of pseudogout by granulocyte colony-stimulating factor. Ann Intern Med 1996; 125:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/12\">",
"      Bong D, Bennett R. Pseudogout mimicking systemic disease. JAMA 1981; 246:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/13\">",
"      Bennett RM, Mall JC, McCarty DJ. Pseudogout in acute neuropathic arthropathy. A clue to pathogenesis? Ann Rheum Dis 1974; 33:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/14\">",
"      Gerster JC, Vischer TL, Fallet GH. Destructive arthropathy in generalized osteoarthritis with articular chondrocalcinosis. J Rheumatol 1975; 2:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/15\">",
"      Richards AJ, Hamilton EB. Destructive arthropathy in chondrocalcinosis articularis. Ann Rheum Dis 1974; 33:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/16\">",
"      Cabre P, Pascal-Moussellard H, Kaidomar S, et al. Six cases of cervical ligamentum flavum calcification in Blacks in the French West Indies. Joint Bone Spine 2001; 68:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/17\">",
"      Muthukumar N, Karuppaswamy U. Tumoral calcium pyrophosphate dihydrate deposition disease of the ligamentum flavum. Neurosurgery 2003; 53:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/18\">",
"      Gerster JC, Lagier R, Boivin G, Schneider C. Carpal tunnel syndrome in chondrocalcinosis of the wrist. Clinical and histologic study. Arthritis Rheum 1980; 23:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/19\">",
"      Bjelle A, Crocker P, Willoughby D. Ultra-microcrystals in pyrophosphate arthropathy. Crystal identification and case report. Acta Med Scand 1980; 207:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/20\">",
"      Gordon C, Swan A, Dieppe P. Detection of crystals in synovial fluids by light microscopy: sensitivity and reliability. Ann Rheum Dis 1989; 48:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/21\">",
"      Schumacher HR Jr, Sieck MS, Rothfuss S, et al. Reproducibility of synovial fluid analyses. A study among four laboratories. Arthritis Rheum 1986; 29:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/22\">",
"      Hasselbacher P. Variation in synovial fluid analysis by hospital laboratories. Arthritis Rheum 1987; 30:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/23\">",
"      Yamakawa K, Iwasaki H, Masuda I, et al. The utility of alizarin red s staining in calcium pyrophosphate dihydrate crystal deposition disease. J Rheumatol 2003; 30:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/24\">",
"      Adamson TC 3rd, Resnik CS, Guerra J Jr, et al. Hand and wrist arthropathies of hemochromatosis and calcium pyrophosphate deposition disease: distinct radiographic features. Radiology 1983; 147:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/25\">",
"      Martel W, Champion CK, Thompson GR, Carter TL. A roentgenologically distinctive arthropathy in some patients with the pseudogout syndrome. Am J Roentgenol Radium Ther Nucl Med 1970; 109:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/26\">",
"      Resnick D, Niwayama G. Carpal instability in rheumatoid arthritis and calcium pyrophosphate deposition disease. Pathogenesis and roentgen appearance. Ann Rheum Dis 1977; 36:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/27\">",
"      Lagier R. Rare femoral erosions and osteoarthrosis of the knee associated with chondrocalcinosis. A histological study of this cortical remodelling. Virchows Arch A Pathol Anat Histol 1974; 364:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/28\">",
"      Martel W, McCarter DK, Solsky MA, et al. Further observations on the arthropathy of calcium pyrophosphate crystal deposition disease. Radiology 1981; 141:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/29\">",
"      Frediani B, Filippou G, Falsetti P, et al. Diagnosis of calcium pyrophosphate dihydrate crystal deposition disease: ultrasonographic criteria proposed. Ann Rheum Dis 2005; 64:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/30\">",
"      Jones AC, Chuck AJ, Arie EA, et al. Diseases associated with calcium pyrophosphate deposition disease. Semin Arthritis Rheum 1992; 22:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7785/abstract/31\">",
"      Ishida T, Dorfman HD, Bullough PG. Tophaceous pseudogout (tumoral calcium pyrophosphate dihydrate crystal deposition disease). Hum Pathol 1995; 26:587.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1668 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.111.122.2-0C8C6D5D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_38_7785=[""].join("\n");
var outline_f7_38_7785=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H81271603\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H272267074\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Asymptomatic CPPD crystal deposition (\"asymptomatic CPPD\")",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pseudogout (\"acute CPP crystal arthritis\")",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pseudo-rheumatoid arthritis (\"chronic CPP crystal inflammatory arthritis\")",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pseudo-osteoarthritis (\"OA with CPPD\")",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pseudo-neuropathic joint disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Spinal involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SYNOVIAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Synovial fluid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Synovial tissue",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      IMAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Plain film radiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Chondrocalcinosis (\"cartilage calcification\")",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Degenerative changes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Other radiographic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Ultrasonographic findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Screening for associated diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H81271603\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/1668\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1668|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/12/207\" title=\"diagnostic image 1\">",
"      Chondrocalcinosis of knee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/41/660\" title=\"diagnostic image 2\">",
"      Cartilagenous calcification US",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1668|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/5/37981\" title=\"picture 1\">",
"      Intracellular CPPD crystal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/26/37282\" title=\"picture 2\">",
"      Crystals in synovial fluid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1668|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/26/23979\" title=\"table 1\">",
"      Diseases associated with CPPD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=related_link\">",
"      Clinical manifestations and diagnosis of gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=related_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12056?source=related_link\">",
"      Clinical manifestations of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39527?source=related_link\">",
"      Diabetic neuropathic arthropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/32/33287?source=related_link\">",
"      Diagnosis and classification of osteoarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/55/6010?source=related_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28904?source=related_link\">",
"      Evaluation of the adult with monoarticular pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/15/34039?source=related_link\">",
"      Evaluation of the adult with polyarticular pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6375?source=related_link\">",
"      Pathogenesis and etiology of calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/15/34033?source=related_link\">",
"      Patient information: Pseudogout (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/9/10386?source=related_link\">",
"      Patient information: Pseudogout (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=related_link\">",
"      Spinal cord tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18134?source=related_link\">",
"      Treatment of calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_38_7786="Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy";
var content_f7_38_7786=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/38/7786/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/38/7786/contributors\">",
"     Thomas Levin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/38/7786/contributors\">",
"     C Michael Gibson, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/38/7786/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/38/7786/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/38/7786/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/38/7786/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/38/7786/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restoration of infarct vessel patency has become one of the cornerstones of treatment for acute ST elevation myocardial infarction (STEMI). Intravenous fibrinolytic agents are the most widely used means for acute reestablishment of vessel patency, and their use has become routine as large clinical trials have shown their unequivocal benefit. In comparison, there is no apparent benefit in patients with non-ST elevation (non-Q wave) MI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=see_link\">",
"     \"Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22421?source=see_link\">",
"     \"Fibrinolytic (thrombolytic) agents in unstable angina and acute non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The various markers that are used for establishing the efficacy of fibrinolysis are discussed here. The major issues in fibrinolytic therapy of acute STEMI including efficacy, choice of agent, indications and contraindications, the concurrent use of other agents, and the role of primary angioplasty as an alternative to fibrinolysis are addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MARKERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     TIMI flow grade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrinolytic efficacy has been assessed using the TIMI (Thrombolysis in Myocardial Infarction trial) flow grade classification. This classification characterizes coronary blood flow in the infarct-related artery, which is usually measured at 60 to 90 minutes after the administration of fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      TIMI 0 refers to the absence of any antegrade flow beyond a coronary occlusion",
"     </li>",
"     <li>",
"      TIMI 1 flow is faint antegrade coronary flow beyond the occlusion, although filling of the distal coronary bed is incomplete",
"     </li>",
"     <li>",
"      TIMI 2 flow is delayed or sluggish antegrade flow with complete filling of the distal territory",
"     </li>",
"     <li>",
"      TIMI 3 flow is normal flow which fills the distal coronary bed completely",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are a number of factors that can influence TIMI flow grade after fibrinolysis, including hemodynamics, local anatomy, amount of residual thrombus, and cellular factors (",
"    <a class=\"graphic graphic_figure graphicRef52322 \" href=\"UTD.htm?35/59/36787\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Angiography performed within four to six hours of symptom onset in patients with STEMI reveals complete occlusion in 80 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Epicardial patency (TIMI 2 or 3 flow) following fibrinolytic therapy was achieved in 73 percent in a meta-analysis of five trials of almost 4000 patients in whom angiographic data were obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/6\">",
"     6",
"    </a>",
"    ]. However, there may be differences between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    (recombinant tissue-type plasminogen activator or tPA) and streptokinase with regard to time to treatment and vessel patency. This was illustrated in a study of 481 patients that analyzed patency rates at 90 minutes based upon treatment &lt;3 or &ge;3 hours after symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/7\">",
"     7",
"    </a>",
"    ]. The patency rate (TIMI 2 or 3 flow) was similar with alteplase (72 percent) in the two groups but was significantly higher when streptokinase was administered early rather than late (87 versus 60 percent) (",
"    <a class=\"graphic graphic_figure graphicRef63689 \" href=\"UTD.htm?29/9/29853\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of TIMI 3 (normal) flow at 60 or 90 minutes is an important predictor of outcome (",
"    <a class=\"graphic graphic_figure graphicRef75629 \" href=\"UTD.htm?15/40/16013\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Only restoration of normal epicardial flow has been associated with improved left ventricular function and survival, since the outcome of patients with TIMI 2 flow is similar to those with only TIMI 0 or 1 flow [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/6,11-13\">",
"     6,11-13",
"    </a>",
"    ]. This was illustrated in the meta-analysis of five trials cited above in which short-term mortality (in-hospital to 30 days in the different trials) was 3.7, 7.0, and 8.8 percent among patients with TIMI grade 3, 2, and",
"    <span class=\"nowrap\">",
"     0/1",
"    </span>",
"    flow, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients with TIMI 3 flow also had lower peak creatine kinase levels, fewer regional wall motion abnormalities, and a smaller decrease in ejection fraction than those with TIMI 2 flow.",
"   </p>",
"   <p>",
"    The importance of TIMI 3 flow illustrates one of the limitations of fibrinolysis in patients with an STEMI. TIMI 3 flow is achieved in only 50 to 60 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/6,8,14\">",
"     6,8,14",
"    </a>",
"    ] (53 percent in the meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/6\">",
"     6",
"    </a>",
"    ]) compared to over 90 percent with primary percutaneous coronary intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several possible explanations for worse outcomes with TIMI 2 compared to TIMI 3 flow at 60 to 90 minutes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most TIMI grade 2 flow is observed in the left anterior descending artery (an infarct artery location associated with high mortality), while most TIMI grade 3 flow is observed in the right coronary artery (an infarct location associated with lower mortality) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is angiographic evidence of TIMI 2 flow may reflect advanced microvascular damage [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      TIMI 2 flow at 90 minutes may reflect incomplete clot lysis. This was illustrated in a study from the GUSTO-I investigators, which evaluated 914 patients who underwent coronary angiography at both 90 minutes and 5 to 7 days [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/19\">",
"       19",
"      </a>",
"      ]. TIMI 2 flow was observed in 278 patients at 90 minutes; 67 percent of these patients improved to TIMI 3 flow at follow-up. The patients with late improvement in flow had larger caliber vessels and a lower incidence of visible clot. Their left ventricular function was intermediate between those who had no reperfusion (TIMI 0 or 1 flow) and those with complete reperfusion (TIMI 3 flow).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although most of the studies have reported the benefit of TIMI 3 flow on short term mortality, achieving full patency has long-term mortality benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The GUSTO-I trial evaluated the importance of TIMI flow grade in 2431 patients with a myocardial infarction who received fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/20\">",
"     20",
"    </a>",
"    ]. The two-year mortality for those with TIMI 3 flow was 7.9 percent compared to 15.7 percent for those with lesser flow grades (hazard ratio 0.48) (",
"    <a class=\"graphic graphic_figure graphicRef70952 \" href=\"UTD.htm?9/52/10061\">",
"     figure 4",
"    </a>",
"    ). When survival after 30 days was analyzed separately, there was an additional 3.3 percent mortality in those with TIMI 3 flow compared with 8.3 percent for lesser flow grades (hazard ratio 0.39); thus, the benefit of having TIMI 3 flow continued after the acute phase (a gain of 5 lives per 100 during this period). This benefit was independent of left ventricular ejection fraction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Myocardial tissue perfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The restoration of epicardial coronary artery blood flow does not necessarily result in normalization of myocardial perfusion. Despite epicardial vessel patency, some patients have a profound reduction in antegrade coronary blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. This is referred to as the \"no-reflow phenomenon.\" It is presumed to reflect microvascular dysfunction.",
"   </p>",
"   <p>",
"    Multiple factors probably contribute to no-reflow. These include myocardial necrosis and stunning, reperfusion injury resulting from oxygen free radical production, microvascular damage, distal embolization of plaque",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombus, release of active tissue factor from the dissected plaque [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/24\">",
"     24",
"    </a>",
"    ], and alpha-adrenergic-mediated vasoconstriction [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In clinical studies, no-reflow has often been defined as a TIMI flow grade &le;2 in the absence of macrovascular obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. However, microvascular perfusion may also be reduced in patients with TIMI grade 3 flow. Other measures that have been developed to assess microvascular perfusion include the TIMI frame count and the TIMI myocardial perfusion (TMP) grade (or myocardial blush grade) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/21,28,29\">",
"     21,28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     TIMI frame count",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TIMI frame count is the number of cine frames required for dye to first reach standardized distal coronary landmarks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/30\">",
"     30",
"    </a>",
"    ]. Since the left anterior descending artery is usually longer than the other major arteries, the TIMI frame count for this vessel is often higher and a correction is made.",
"   </p>",
"   <p>",
"    To normalize the values, the TIMI frame count of the left anterior descending artery is divided by 1.7, the ratio of the unadjusted mean TIMI frame count of the left anterior descending artery to the mean frame count of the other arteries; this is called the corrected TIMI frame count [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/17\">",
"     17",
"    </a>",
"    ]. Factors such as age, body size, systemic arterial pressure, and sex have only a small effect on the absolute corrected TIMI frame count [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/31\">",
"     31",
"    </a>",
"    ], which correlates with stenosis severity in the infarct artery, infarct zone regional wall motion, and peak CK levels after fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The corrected TIMI frame count appears to be effective in defining low-risk and high-risk patient subsets. One study measured the TIMI frame count in 1248 patients treated with fibrinolytic agents in the TIMI 4, 10, and 10B trials [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/33\">",
"     33",
"    </a>",
"    ]. The following findings were noted (",
"    <a class=\"graphic graphic_figure graphicRef73547 \" href=\"UTD.htm?21/0/21518\">",
"     figure 5",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who died in the hospital had a higher frame count (slower flow) compared to survivors (70 versus 50); a higher frame count was also observed in those who died by 30 to 42 days. In a multivariate model that excluded the TIMI flow grade, there was a 0.7 percent increase in absolute mortality for every 10-frame rise.",
"     </li>",
"     <li>",
"      The frame count further stratified patients with TIMI grade III flow. Although a frame count &le;40 is associated with TIMI grade III flow, those with a frame count &le;20 had a 7.9 percent incidence of in-hospital adverse events (death, recurrent infarction, shock, congestive heart failure or left ventricular ejection fraction &le;40 percent) compared to 15.5 percent for those with a frame count between 21 and 40.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The TIMI frame count is also a predictor of long-term outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/21,34\">",
"     21,34",
"    </a>",
"    ]. As an example, one study performed coronary angiography three weeks after an acute myocardial infarction in 882 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/34\">",
"     34",
"    </a>",
"    ]. The corrected TIMI frame count was associated with five-year, but not 10-year, survival. Although the TIMI frame count provided additional prognostic information within each TIMI flow grade, it was not superior to the TIMI flow grade.",
"   </p>",
"   <p>",
"    Although intraobserver and interobserver reproducibility of the TIMI frame count is good, there are factors that can introduce variability and decrease the TIMI frame count; these include nitrate use, increasing heart rate, and injection of dye during the beginning of diastole (versus the beginning of systole) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     TIMI myocardial perfusion grade",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TIMI myocardial perfusion (TMP) grade is a simple angiographic method that was developed to characterize myocardial perfusion. The TMP grade classification is [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TMP grade 0 indicates no apparent tissue level perfusion, ie, no ground-glass appearance of blush or opacification of the myocardium, in the region of the culprit artery.",
"     </li>",
"     <li>",
"      TMP grade 1 indicates the presence of myocardial blush but no clearance from the microvasculature, ie, the blush or stain was present on the next injection.",
"     </li>",
"     <li>",
"      TMP grade 2 indicates that the blush clears slowly, ie, the blush is strongly persistent and diminishes minimally or not at all during three cardiac cycles of the washout phase.",
"     </li>",
"     <li>",
"      TMP grade 3 indicates that blush begins to clear during washout,",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ie, the blush is minimally persistent after three cardiac cycles of washout.",
"   </p>",
"   <p>",
"    TMP grade is a predictor of outcome after fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/21,29,36\">",
"     21,29,36",
"    </a>",
"    ]. The relationship between TMP grade and mortality was examined in 762 patients enrolled in the TIMI 10B trial [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/36\">",
"     36",
"    </a>",
"    ]. The 30-day mortality was lowest in those with TMP grade 3 (2 percent), intermediate in those with TMP grade 2 (4.4 percent), and highest in those with TMP grade 0 or 1 (6 percent). This relationship persisted even in patients with TIMI grade 3 flow and allowed for further risk stratification: the 30 day mortality was 0.7 percent for TMP grade 3, 2.9 percent for TMP grade 2, and 5 percent for TMP grade 0 or 1.",
"   </p>",
"   <p>",
"    The TMP grade was an independent predictor of mortality even after adjusting for the presence of TIMI flow grade 3, the corrected TIMI frame count, and other clinical parameters. The TMP grade remained predictive of improved survival after a two year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognostic importance of a higher TMP grade may be explained, in part, by its association with infarct size as measured with single photon emission computed tomography (SPECT) imaging (the higher the grade, the smaller the infarction) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The TMP grade is also predictive of outcome in patients with an acute ST elevation MI who are treated with primary percutaneous coronary intervention (PCI) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/29\">",
"     29",
"    </a>",
"    ]. Such patients are significantly more likely to achieve TMP grade",
"    <span class=\"nowrap\">",
"     2/3",
"    </span>",
"    than those treated with fibrinolytic therapy (71 versus 48 percent in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=see_link\">",
"     \"Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     ST segment elevation resolution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resolution of ST segment elevation after fibrinolytic therapy has been considered a marker of epicardial and microvascular and tissue-level reperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=see_link\">",
"     \"Electrocardiogram in the diagnosis of myocardial ischemia and infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The degree of ST segment resolution is predictive of short-, medium, and long-term outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/39-41\">",
"     39-41",
"    </a>",
"    ], at least in part because of its association with infarct-related artery patency (as assessed by TIMI flow grade [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/38,42\">",
"     38,42",
"    </a>",
"    ] or myocardial perfusion grade [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/37,43\">",
"     37,43",
"    </a>",
"    ]) and smaller infarct size [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Resolution and artery patency'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The prognostic importance of ST segment resolution was evaluated in 1909 patients who received fibrinolytic therapy within six hours of symptom onset [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/39\">",
"     39",
"    </a>",
"    ]. The inability to resolve ST segment elevation within three hours was significantly associated with increased mortality and infarct size. The 35 day mortality rate for complete (&ge;70 percent), partial (30 to 70 percent), or no resolution of ST segment elevation at three hours was 2.5, 4.3 and 17.5 percent respectively. This relationship was observed in both anterior and inferior wall infarction. The degree of ST segment resolution by three hours was the most powerful clinical predictor of 35 day mortality (",
"    <a class=\"graphic graphic_figure graphicRef73003 \" href=\"UTD.htm?9/59/10174\">",
"     figure 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The actual amount of ST segment deviation in a single ECG lead that persists at 90 minutes after fibrinolysis is also predictive of medium-term outcome. One report of 2719 patients identified three risk groups based upon the extent of ST segment deviation at 90 minutes (",
"    <a class=\"graphic graphic_figure graphicRef75462 \" href=\"UTD.htm?7/0/7182\">",
"     figure 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High risk patients with an anterior MI had a &gt;3 mm ST segment elevation in any lead or a new bundle branch block; those with an inferior wall MI had &gt;2 mm ST segment elevation in any of the inferior leads or V5 to V6 or &gt;2 mm ST segment depression in any leads V1 to V4.",
"     </li>",
"     <li>",
"      Low risk patients with an anterior wall MI had &le;2 mm ST segment elevation and no bundle branch block; those with an inferior wall MI had &lt;1 mm ST segment elevation or depression and no bundle branch block.",
"     </li>",
"     <li>",
"      Patients at neither high nor low risk comprised the medium risk group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among those at low, medium, and high risk, the mortality was 3, 7, and 16 percent at six months and 4, 9, and 19 percent at one year.",
"   </p>",
"   <p>",
"    The degree of ST segment resolution is also predictive of late survival. In a review of 766 patients followed for a median of 6.3 years, complete, partial, or no ST segment resolution was significantly associated with survival at five (90, 83, and 77 percent, respectively) and 10 years (74, 71, and 55 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Time to resolution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most studies have found that an assessment of ST segment resolution at 90 to 180 minutes is a predictor of outcome, although an earlier measurement might facilitate a more rapid decision about the use of angioplasty as a \"rescue\" for establishing vessel patency. This issue was addressed by comparing ST segment resolution at 60 versus 90 minutes in 1797 patients enrolled in the InTIME-II trial [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/44\">",
"     44",
"    </a>",
"    ]. Although ST segment resolution was less often seen at 60 minutes (33 versus 41 percent at 90 minutes), such patients had a lower mortality at 30 days and one year compared to those with resolution at 90 minutes (1.7 versus 3.1 percent and 2.7 versus 4.7 percent, respectively). These findings suggest that ST segment changes at 60 minutes should be routinely determined. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Rapid resolution of ST segment elevation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A later report of patients from both InTIME-II and TIMI 14 found that the odds of achieving complete ST segment resolution at 60 to 90 minutes fell by 6 percent for each additional hour from symptom onset to initiation of fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although early (&le;180 minutes) ST segment resolution is associated with a favorable outcome, the utility of later ST segment resolution, which is more frequently seen, is uncertain. This issue was evaluated in a substudy of the ASSENT 2 trial of 16,949 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/46\">",
"     46",
"    </a>",
"    ]. At 24 to 36 hours, complete, partial, or no resolution of the ST segment was observed in 51, 35, and 14 percent, respectively; the mortality at one year was 5, 8, and 10 percent, respectively. Patients receiving a fibrinolytic earlier (less than two hours of symptom onset) were more likely to have complete ST resolution compared to those treated between two to four and greater than four hours. However, within each category of ST segment resolution, patients treated within two hours had a lower one year mortality than those treated later.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Resolution and artery patency",
"    </span>",
"    &nbsp;&mdash;&nbsp;ST segment elevation resolution correlates with infarct-related artery patency (as assessed by TIMI flow grade [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/38,42\">",
"     38,42",
"    </a>",
"    ] or myocardial perfusion grade [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/37,43\">",
"     37,43",
"    </a>",
"    ]) and better outcomes (",
"    <a class=\"graphic graphic_figure graphicRef66373 \" href=\"UTD.htm?38/52/39758\">",
"     figure 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This was seen in the TIMI 14 trial of 444 patients with an interpretable ECG who underwent angiography at 90 minutes after fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/42\">",
"     42",
"    </a>",
"    ]. Seventy-nine percent of those with complete (&ge;70 percent) ST segment resolution had TIMI grade 3 flow and their 30 day mortality was 1 percent. In contrast, patients with partial or no ST segment resolution were significantly less likely to have TIMI grade 3 flow (50 and 44 percent, respectively) and had a higher 30-day mortality (4.2 and 5.9 percent, respectively). Although patients without ST segment resolution may still have a patent coronary artery, they are nevertheless at increased risk for mortality, which is likely due to extensive microvascular and tissue injury.",
"   </p>",
"   <p>",
"    Similar results were observed in a study of 258 patients enrolled in TAMI-7 and GUSTO-I trials [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/47\">",
"     47",
"    </a>",
"    ]. Resolution of ST segment elevation by &ge;50 percent was an independent predictor of the combined end point of in-hospital mortality and heart failure, while the TIMI flow grade was not a predictor. Among patients with TIMI flow grade 0 or 1, ST segment resolution identified a group with a lower risk of death or heart failure (17 versus 37 percent without ST segment resolution).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Resolution and wall motion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early resolution of ST segment elevation adds additional information about wall motion in the infarct zone in patients who have a patent coronary artery (TIMI flow grade 2 or 3). This was evaluated in a study of 134 patients who underwent angiography 99 minutes after streptokinase therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/48\">",
"     48",
"    </a>",
"    ]. Those with TIMI 2 or 3 flow who did not have stable ST segment recovery (50 percent decrease in ST segment elevation sustained for &ge;4 hours) by 90 minutes had a greater degree of wall motion abnormalities in the infarct zone at 48 hours compared to those who had resolution of ST segment elevation. In patients with TIMI 0 or 1 flow, there was no relationship between regional wall motion and ST segment recovery. With multivariate analysis, time to stable ST segment recovery was a predictor of infarct zone wall motion, independent of TIMI flow grade and the time from symptom onset to streptokinase therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Rapid resolution of ST segment elevation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid resolution of ST segment elevation in patients with biochemical markers of reperfusion, ie, early peak CK after fibrinolysis, identifies those with early artery recanalization who have adequate myocardial reperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Improved outcomes have been described in these patients. This was illustrated in a report of 162 patients with early peak CK (&le;12 hours) after fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/50\">",
"     50",
"    </a>",
"    ]. Regardless of the site of the infarction, those with rapid resolution of ST segment elevation had lower peak CK levels and better left ventricular ejection fractions compared to those without concomitant rapid resolution, despite similar patency rates of the infarct-related artery. At two year follow-up, the patients with rapid ST segment resolution had significantly lower rates of heart failure (1 versus 13 percent) and mortality (2 versus 13 percent), but a higher incidence of reinfarction (27 versus 9 percent) (",
"    <a class=\"graphic graphic_figure graphicRef53047 \" href=\"UTD.htm?26/23/27005\">",
"     figure 9",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Some patients who are rapidly reperfused do not develop a cardiac biomarker elevation. The frequency with which this occurs was illustrated in the ASSENT-3 trial, which included 5470 patients treated with fibrinolysis for acute STEMI: 25 percent of those treated within one hour of symptom onset and 13 percent of patients overall had no enzyme elevation, defined as maximal CK &le;2 times the upper limit of normal plus typical evolution of ECG changes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/51\">",
"     51",
"    </a>",
"    ]. These patients had smaller infarcts and improved outcomes, particularly if there was &ge;70 percent ST segment elevation resolution at 60 minutes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link&amp;anchor=H1#H1\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Combined end point",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of a TIMI flow grade of 3, a TIMI myocardial perfusion grade of 3, and ST segment resolution identifies a population of patients with an especially low rate of adverse events. In an analysis of data from three fibrinolysis trials, 117 of 649 patients (18 percent) achieved all three end points at 60 minutes after the administration of fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/52\">",
"     52",
"    </a>",
"    ]. Among patients achieving all three end points, the 30-day rates of mortality and heart failure were 0 and 0.9 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Persistent ST segment depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Also of prognostic importance is persistent ST segment depression in the non-infarct related leads. One study of 221 consecutive patients who received fibrinolytic therapy for their first MI found that persistent ST segment depression in these leads on a predischarge ECG predicted a worse survival at 31 months (55 versus 81 percent when ST segment depression resolved and 94 percent when no ST segment depression was present) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/53\">",
"     53",
"    </a>",
"    ]. This relationship was seen in those with either an anterior or an inferior wall MI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Recurrent ST segment changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent ST segment shift (elevation or depression) within 6 to 24 hours of initial resolution of ST segment elevation after fibrinolytic therapy identifies patients at high risk. In GUSTO-I, for example, 33 percent of patients had a new ST segment shift; their 30 day (7.8 versus 2.3 percent) and 1 year mortality (10.3 versus 5.7 percent) was significantly higher compared to patients without an ST shift (",
"    <a class=\"graphic graphic_figure graphicRef63705 \" href=\"UTD.htm?33/2/33838\">",
"     figure 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Presence of Q waves",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another important electrocardiographic feature is the presence of Q waves on a baseline ECG or the emergence of Q waves after fibrinolytic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Preexisting pathologic Q waves or T wave inversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of pathologic Q waves or T wave inversions on the presenting ECG is associated with a poorer result from fibrinolysis, perhaps because they reflect a longer duration of coronary occlusion. In one study of 362 patients treated with streptokinase, the following findings were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TIMI grade III flow was more commonly seen after treatment in those without Q waves prior to therapy (55 versus 35 percent, p&lt;0.001)",
"     </li>",
"     <li>",
"      TIMI grade III flow was more often achieved in patients without T wave inversions (50 versus 30 percent of those with T wave inversions, p&lt;0.002)",
"     </li>",
"     <li>",
"      TIMI grade III flow occurred in only 20 percent of those with both Q waves and T wave inversions compared to 50 percent of the remaining patients",
"     </li>",
"     <li>",
"      Regional wall motion abnormalities at 48 hours were more common in those with pathologic Q waves [",
"      <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/56\">",
"       56",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Absence of Q waves after therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absence of Q waves among patients with an STEMI predicts a less severe infarction and better outcomes, whether or not reperfusion therapy is given. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4521?source=see_link&amp;anchor=H10#H10\">",
"     \"Electrocardiogram in the prognosis of myocardial infarction or unstable angina\", section on 'Presence or absence of new Q waves'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several reports have evaluated the outcomes of such patients after fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/50,57-59\">",
"     50,57-59",
"    </a>",
"    ]. The importance of Q waves was addressed in a subset study from the GUSTO-I trial of fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/57\">",
"     57",
"    </a>",
"    ]. Among 21,570 patients who did not have confounding ECG factors or a prior MI, Q waves did not develop in 4601 (21.3 percent). Compared to the Q wave group, patients with a non-Q wave STEMI had a significantly lower rate of heart failure (8.5 versus 13.9 percent) and significant reductions in mortality in-hospital and at 30 days (adjusted mortality 4.8 versus 5.3 percent) and one year.",
"   </p>",
"   <p>",
"    Better outcomes and a less severe MI were also noted in a second, smaller subset analysis from GUSTO-I [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/58\">",
"     58",
"    </a>",
"    ]. Patients without Q waves had a significantly higher left ventricular ejection fraction (66 versus 57 percent) and higher rates of survival at all time points including two years (6.3 versus 10.1 percent). The infarct-related artery was significantly less likely to be anterior (33 versus 42 percent) and more likely to be distal. The degree of reperfusion was also greater as evidenced by a greater likelihood of early (77 versus 65 percent at 90 minutes) and complete patency in the infarct-related artery (54 versus 44 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Biochemical markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biochemical markers, particularly CK-MB and troponin T, are noninvasive markers of reperfusion. The 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    task force concluded that serial measurements of cardiac biomarkers can be useful to provide supportive noninvasive evidence of reperfusion after fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the detection of reperfusion, a rapidly rising and falling biomarker such as CK-MB or myoglobin may be preferable to a marker with prolonged elevation of serum concentration, such as troponins [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. In one study, the slope of CK-MB release, in conjunction with clinical parameters, yielded the greatest separation between groups of patients having TIMI 0 or 1 and TIMI 2 or 3 flow [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=see_link\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28101?source=see_link\">",
"     \"Biomarkers of cardiac injury other than troponins and creatine kinase\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic performance of various biochemical markers was evaluated in the TIMI 10B trial of 442 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/63\">",
"     63",
"    </a>",
"    ]. Serum concentrations of myoglobin, troponin I, and CK-MB were measured at baseline and 60 minutes after initiation of fibrinolytic therapy; a 60 minute-to-baseline ratio of &ge;4 for myoglobin, &ge;3.3 for CK-MB, and &ge;2 for troponin I yielded a probability of TIMI 2 or 3 flow of 90, 88, and 87 percent, respectively.",
"   </p>",
"   <p>",
"    A clinical limitation to these observations is that troponins are the preferred marker for the diagnosis of an acute MI, CK-MB is not always ordered, and myoglobin in rarely measured.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Infarct size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple endpoints have been used as a marker of efficiency of reperfusion therapy in acute myocardial infarction in various fibrinolytic trials, including global and regional left ventricular function, early coronary artery patency, and clinical outcomes. Another important surrogate end point for both early and late mortality is infarct size, which has been used in various studies as a marker of efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various methods have been used clinically to determine infarct size, including global left ventricular function or ejection fraction, end systolic volume, regional wall motion, creatine kinase release, thallium infarct size, and QRS score based on evolutionary ST and T wave changes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/65\">",
"     65",
"    </a>",
"    ]. The available evidence suggests that radionuclide myocardial perfusion imaging with 99m-technetium sestamibi is the best option (",
"    <a class=\"graphic graphic_figure graphicRef79558 \" href=\"UTD.htm?25/25/26013\">",
"     figure 11",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/66\">",
"     66",
"    </a>",
"    ]. It is closely associated with the other measures and parameters that have been used clinically and also correlates with actual fibrosis in human hearts [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Reperfusion arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;An additional marker of successful reperfusion after fibrinolytic (or mechanical) therapy has been the development of \"reperfusion arrhythmias\". The evidence is best for an accelerated idioventricular rhythm (AIVR), although AIVR is neither a sensitive nor very specific marker for successful reperfusion. In comparison, ventricular tachycardia and ventricular fibrillation are often associated with persistent occlusion not patency of the infarct-related artery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12570?source=see_link\">",
"     \"Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Procoagulant markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of fibrinolytic therapy to patients with an acute myocardial infarction results in an increase in thrombin activity, which may contribute to failure to achieve initial reperfusion or in the development of reocclusion after successful fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. In a study from the TIMI-5 investigators, increased levels of markers of procoagulant activity (fibrinopeptide A, thrombin-antithrombin III complexes, and prothrombin fragment 1.2) at one hour were associated with higher mortality, lower TIMI flow (grades 0, I, or II), and a possible increase in risk of recurrent ischemia after fibrinolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar data were reported in 292 patients by the GUSTO-I investigators [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/71\">",
"     71",
"    </a>",
"    ]. Fibrinopeptide A (FPA) levels were elevated at baseline and increased after streptokinase and subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy. The increase in FPA was attenuated by intravenous heparin but thrombin generation, as measured by prothrombin fragment 1 + 2, was unaffected. Elevated baseline and 12 hour concentrations of procoagulant markers were associated with greater 30 day mortality and reinfarction rates (",
"    <a class=\"graphic graphic_figure graphicRef61441 \" href=\"UTD.htm?4/45/4831\">",
"     figure 12",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    One possible mechanism by which this might occur is that plasmin generation activates the kallikrein-contact phase system, resulting in thrombin activation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/72\">",
"     72",
"    </a>",
"    ]. Procoagulant activity may be more marked and of longer duration after streptokinase therapy than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    , which might contribute to the worse outcomes with streptokinase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PREDICTION OF FAILED FIBRINOLYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above discussion has assessed the value of individual tests as markers of efficacy for fibrinolysis. The TIMI 14 trial assessed the combined use of several noninvasive markers to identify patients with angiographic evidence of failed fibrinolysis (TIMI flow grade &lt;3) who are candidates for rescue angioplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/73\">",
"     73",
"    </a>",
"    ]. The markers included &lt;50 percent ST resolution at 90 minutes, presence of chest pain at time of angiography, and reduced washout of myoglobin (ratio of 60 minute to baseline myoglobin levels &lt;4). Patients with 0, 1, 2 or 3 criteria had a 17, 24, 35, and 76 percent probability, respectively, of failing to achieve TIMI flow grade III and a 0, 6, 18, and 57 percent probability, respectively, of having an occluded artery.",
"   </p>",
"   <p>",
"    At present, the clinical decision to perform angiography followed by rescue PCI, if appropriate, or perhaps repeat fibrinolysis is primarily based upon strong clinical suspicion of primary failure. The major clinical clues are continuing severe or worsening chest pain, persistent or worsening ST elevation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hemodynamic instability or severe heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/38/7786/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction\", section on 'Primary failure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66248293\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following parameters predict the possibility of unsuccessful reperfusion after fibrinolytic therapy, which has been referred to as failed fibrinolysis (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Prediction of failed fibrinolysis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Severe or worsening chest pain.",
"     </li>",
"     <li>",
"      Persistent of worsening ST segment elevation on the electrocardiogram. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Rapid resolution of ST segment elevation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hemodynamic instability or worsening heart failure.",
"     </li>",
"     <li>",
"      Ventricular tachycardia and ventricular fibrillation are often associated with persistent occlusion not patency of the infarct-related artery. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Reperfusion arrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following angiographic and clinical parameters are associated with worse long-term prognosis:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Less than TIMI 3 flow grade. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'TIMI flow grade'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evidence of the \"no-reflow phenomenon\". (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Myocardial tissue perfusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lack of resolution of ST segment elevation within three hours. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'ST segment elevation resolution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Persistent ST segment depression in the non-infarct related leads. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Persistent ST segment depression'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/1\">",
"      Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/2\">",
"      Tan WA, Moliterno DJ. TIMI flow and surrogate end points: what you see is not always what you get. Am Heart J 1998; 136:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/3\">",
"      Gibson CM, Murphy S, Menown IB, et al. Determinants of coronary blood flow after thrombolytic administration. TIMI Study Group. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1999; 34:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/4\">",
"      DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/5\">",
"      DeWood MA, Spores J, Hensley GR, et al. Coronary arteriographic findings in acute transmural myocardial infarction. Circulation 1983; 68:I39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/6\">",
"      Anderson JL, Karagounis LA, Califf RM. Metaanalysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. Am J Cardiol 1996; 78:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/7\">",
"      Steg PG, Laperche T, Golmard JL, et al. Efficacy of streptokinase, but not tissue-type plasminogen activator, in achieving 90-minute patency after thrombolysis for acute myocardial infarction decreases with time to treatment. PERM Study Group. Prospective Evaluation of Reperfusion Markers. J Am Coll Cardiol 1998; 31:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/8\">",
"      An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993; 329:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/9\">",
"      Holmes DR Jr, Califf RM, Topol EJ. Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries. J Am Coll Cardiol 1995; 25:10S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/10\">",
"      Gibson CM, Murphy SA, Marble SJ, et al. Can we replace the 90-minute thrombolysis in myocardial infarction (TIMI) flow grades with those at 60 minutes as a primary end point in thrombolytic trials? TIMI Study Group. Am J Cardiol 2001; 87:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/11\">",
"      Simes RJ, Topol EJ, Holmes DR Jr, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation 1995; 91:1923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/12\">",
"      Karagounis L, Sorensen SG, Menlove RL, et al. Does thrombolysis in myocardial infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. Second Multicenter Thrombolysis Trial of Eminase in Acute Myocardial Infarction. J Am Coll Cardiol 1992; 19:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/13\">",
"      Anderson JL, Karagounis LA, Becker LC, et al. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 Study. Circulation 1993; 87:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/14\">",
"      The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med 1993; 329:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/15\">",
"      Mehta RH, Harjai KJ, Cox D, et al. Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 2003; 42:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/16\">",
"      Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002; 346:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/17\">",
"      Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996; 93:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/18\">",
"      Ito H, Okamura A, Iwakura K, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996; 93:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/19\">",
"      Reiner JS, Lundergan CF, Fung A, et al. Evolution of early TIMI 2 flow after thrombolysis for acute myocardial infarction. GUSTO-1 Angiographic Investigators. Circulation 1996; 94:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/20\">",
"      Ross AM, Coyne KS, Moreyra E, et al. Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial. Circulation 1998; 97:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/21\">",
"      Gibson CM, Cannon CP, Murphy SA, et al. Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation 2002; 105:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/22\">",
"      Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002; 105:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/23\">",
"      Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: a review of mechanisms and therapies. Eur Heart J 2001; 22:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/24\">",
"      Bonderman D, Teml A, Jakowitsch J, et al. Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. Blood 2002; 99:2794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/25\">",
"      Gregorini L, Marco J, Koz&agrave;kov&agrave; M, et al. Alpha-adrenergic blockade improves recovery of myocardial perfusion and function after coronary stenting in patients with acute myocardial infarction. Circulation 1999; 99:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/26\">",
"      Morishima I, Sone T, Okumura K, et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000; 36:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/27\">",
"      Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of 'no-reflow' after percutaneous coronary intervention. Circulation 1994; 89:2514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/28\">",
"      Haager PK, Christott P, Heussen N, et al. Prediction of clinical outcome after mechanical revascularization in acute myocardial infarction by markers of myocardial reperfusion. J Am Coll Cardiol 2003; 41:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/29\">",
"      Dibra A, Mehilli J, Dirschinger J, et al. Thrombolysis in myocardial infarction myocardial perfusion grade in angiography correlates with myocardial salvage in patients with acute myocardial infarction treated with stenting or thrombolysis. J Am Coll Cardiol 2003; 41:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/30\">",
"      French JK, Ellis CJ, Webber BJ, et al. Abnormal coronary flow in infarct arteries 1 year after myocardial infarction is predicted at 4 weeks by corrected Thrombolysis in Myocardial Infarction (TIMI) frame count and stenosis severity. Am J Cardiol 1998; 81:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/31\">",
"      Faile BA, Guzzo JA, Tate DA, et al. Effect of sex, hemodynamics, body size, and other clinical variables on the corrected thrombolysis in myocardial infarction frame count used as an assessment of coronary blood flow. Am Heart J 2000; 140:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/32\">",
"      Amos DJ, French JK, Andrews J, et al. Corrected TIMI frame counts correlate with stenosis severity and infarct zone wall motion after thrombolytic therapy. Am Heart J 2001; 141:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/33\">",
"      Gibson CM, Murphy SA, Rizzo MJ, et al. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis In Myocardial Infarction (TIMI) Study Group. Circulation 1999; 99:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/34\">",
"      French JK, Hyde TA, Straznicky IT, et al. Relationship between corrected TIMI frame counts at three weeks and late survival after myocardial infarction. J Am Coll Cardiol 2000; 35:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/35\">",
"      Abaci A, Oguzhan A, Eryol NK, Ergin A. Effect of potential confounding factors on the thrombolysis in myocardial infarction (TIMI) trial frame count and its reproducibility. Circulation 1999; 100:2219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/36\">",
"      Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000; 101:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/37\">",
"      Angeja BG, Gunda M, Murphy SA, et al. TIMI myocardial perfusion grade and ST segment resolution: association with infarct size as assessed by single photon emission computed tomography imaging. Circulation 2002; 105:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/38\">",
"      de Lemos JA, Braunwald E. ST segment resolution as a tool for assessing the efficacy of reperfusion therapy. J Am Coll Cardiol 2001; 38:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/39\">",
"      Schr&ouml;der R, Wegscheider K, Schr&ouml;der K, et al. Extent of early ST segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial. J Am Coll Cardiol 1995; 26:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/40\">",
"      Schr&ouml;der K, Wegscheider K, Zeymer U, et al. Extent of ST-segment deviation in a single electrocardiogram lead 90 min after thrombolysis as a predictor of medium-term mortality in acute myocardial infarction. Lancet 2001; 358:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/41\">",
"      French JK, Andrews J, Manda SO, et al. Early ST-segment recovery, infarct artery blood flow, and long-term outcome after acute myocardial infarction. Am Heart J 2002; 143:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/42\">",
"      de Lemos JA, Antman EM, Giugliano RP, et al. ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 investigators. Am J Cardiol 2000; 85:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/43\">",
"      Gibson CM, Karha J, Giugliano RP, et al. Association of the timing of ST-segment resolution with TIMI myocardial perfusion grade in acute myocardial infarction. Am Heart J 2004; 147:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/44\">",
"      de Lemos JA, Antman EM, Giugliano RP, et al. Comparison of a 60- versus 90-minute determination of ST-segment resolution after thrombolytic therapy for acute myocardial infarction. In TIME-II Investigators. Intravenous nPA for Treatment of Infarcting Myocardium Early-II. Am J Cardiol 2000; 86:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/45\">",
"      Antman EM, Cooper HA, Gibson CM, et al. Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction; insights from TIMI 14 and InTIME-II. Eur Heart J 2002; 23:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/46\">",
"      Fu Y, Goodman S, Chang WC, et al. Time to treatment influences the impact of ST-segment resolution on one-year prognosis: insights from the assessment of the safety and efficacy of a new thrombolytic (ASSENT-2) trial. Circulation 2001; 104:2653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/47\">",
"      Shah A, Wagner GS, Granger CB, et al. Prognostic implications of TIMI flow grade in the infarct related artery compared with continuous 12-lead ST-segment resolution analysis. Reexamining the \"gold standard\" for myocardial reperfusion assessment. J Am Coll Cardiol 2000; 35:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/48\">",
"      Andrews J, Straznicky IT, French JK, et al. ST-Segment recovery adds to the assessment of TIMI 2 and 3 flow in predicting infarct wall motion after thrombolytic therapy. Circulation 2000; 101:2138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/49\">",
"      Matetzky S, Freimark D, Chouraqui P, et al. The distinction between coronary and myocardial reperfusion after thrombolytic therapy by clinical markers of reperfusion. J Am Coll Cardiol 1998; 32:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/50\">",
"      Lockwood E, Fu Y, Wong B, et al. Does 24-hour ST-segment resolution postfibrinolysis add prognostic value to a Q wave? An ASSENT 2 electrocardiographic substudy. Am Heart J 2003; 146:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/51\">",
"      Taher T, Fu Y, Wagner GS, et al. Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy. J Am Coll Cardiol 2004; 44:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/52\">",
"      Giugliano RP, Sabatine MS, Gibson CM, et al. Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. Am J Cardiol 2004; 93:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/53\">",
"      Bellotti G, Rochitte CE, de Albuquerque CP, et al. Usefulness of ST-segment depression in non-infarct-related electrocardiographic leads in predicting prognosis after thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1997; 79:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/54\">",
"      Langer A, Krucoff MW, Klootwijk P, et al. Prognostic significance of ST segment shift early after resolution of ST elevation in patients with myocardial infarction treated with thrombolytic therapy: the GUSTO-I ST Segment Monitoring Substudy. J Am Coll Cardiol 1998; 31:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/55\">",
"      Wong CK, French JK, Aylward PE, et al. Usefulness of the presenting electrocardiogram in predicting successful reperfusion with streptokinase in acute myocardial infarction. Am J Cardiol 1999; 83:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/56\">",
"      Wong C, French JK, Zambanini A, et al. Relation of pathologic Q waves at presentation and time to streptokinase therapy with early changes in infarct-related artery flow and ventricular wall motion. Am J Cardiol 2001; 88:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/57\">",
"      Barbagelata A, Califf RM, Sgarbossa EB, et al. Thrombolysis and Q wave versus non-Q wave first acute myocardial infarction: a GUSTO-I substudy. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries Investigators. J Am Coll Cardiol 1997; 29:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/58\">",
"      Goodman SG, Langer A, Ross AM, et al. Non-Q-wave versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries-I angiographic substudy. GUSTO-I Angiographic Investigators. Circulation 1998; 97:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/59\">",
"      Andrews J, French JK, Manda SO, White HD. New Q waves on the presenting electrocardiogram independently predict increased cardiac mortality following a first ST-elevation myocardial infarction. Eur Heart J 2000; 21:647.",
"     </a>",
"    </li>",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/61\">",
"      Ohman EM, Christenson RH, Califf RM, et al. Noninvasive detection of reperfusion after thrombolysis based on serum creatine kinase MB changes and clinical variables. TAMI 7 Study Group. Thrombolysis and Angioplasty in Myocardial Infarction. Am Heart J 1993; 126:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/62\">",
"      Christenson RH, Ohman EM, Topol EJ, et al. Assessment of coronary reperfusion after thrombolysis with a model combining myoglobin, creatine kinase-MB, and clinical variables. TAMI-7 Study Group. Thrombolysis and Angioplasty in Myocardial Infarction-7. Circulation 1997; 96:1776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/63\">",
"      Tanasijevic MJ, Cannon CP, Antman EM, et al. Myoglobin, creatine-kinase-MB and cardiac troponin-I 60-minute ratios predict infarct-related artery patency after thrombolysis for acute myocardial infarction: results from the Thrombolysis in Myocardial Infarction study (TIMI) 10B. J Am Coll Cardiol 1999; 34:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/64\">",
"      Miller TD, Christian TF, Hopfenspirger MR, et al. Infarct size after acute myocardial infarction measured by quantitative tomographic 99mTc sestamibi imaging predicts subsequent mortality. Circulation 1995; 92:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/65\">",
"      Adler Y, Zafrir N, Ben-Gal T, et al. Relation between evolutionary ST segment and T-wave direction and electrocardiographic prediction of mycardial infarct size and left ventricular function among patients with anterior wall Q-wave acute myocardial infarction who received reperfusion therapy. Am J Cardiol 2000; 85:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/66\">",
"      Gibbons RJ, Miller TD, Christian TF. Infarct size measured by single photon emission computed tomographic imaging with (99m)Tc-sestamibi: A measure of the efficacy of therapy in acute myocardial infarction. Circulation 2000; 101:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/67\">",
"      Medrano R, Lowry RW, Young JB, et al. Assessment of myocardial viability with 99mTc sestamibi in patients undergoing cardiac transplantation. A scintigraphic/pathological study. Circulation 1996; 94:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/68\">",
"      Berger PB, Ruocco NA, Ryan TJ, et al. Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: results from the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial. J Am Coll Cardiol 1993; 22:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/69\">",
"      Scharfstein JS, Abendschein DR, Eisenberg PR, et al. Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI-5 Investigators. Thrombolysis in Myocardial Infarction. Am J Cardiol 1996; 78:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/70\">",
"      Merlini PA, Bauer KA, Oltrona L, et al. Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J Am Coll Cardiol 1995; 25:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/71\">",
"      Granger CB, Becker R, Tracy RP, et al. Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 1998; 31:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/72\">",
"      Hoffmeister HM, Szabo S, Kastner C, et al. Thrombolytic therapy in acute myocardial infarction: comparison of procoagulant effects of streptokinase and alteplase regimens with focus on the kallikrein system and plasmin. Circulation 1998; 98:2527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/73\">",
"      de Lemos JA, Morrow DA, Gibson CM, et al. Early noninvasive detection of failed epicardial reperfusion after fibrinolytic therapy. Am J Cardiol 2001; 88:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/38/7786/abstract/74\">",
"      Goldman LE, Eisenberg MJ. Identification and management of patients with failed thrombolysis after acute myocardial infarction. Ann Intern Med 2000; 132:556.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 54 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-89768E4622-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_38_7786=[""].join("\n");
var outline_f7_38_7786=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H66248293\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MARKERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TIMI flow grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Myocardial tissue perfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - TIMI frame count",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - TIMI myocardial perfusion grade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ST segment elevation resolution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Time to resolution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Resolution and artery patency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Resolution and wall motion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Rapid resolution of ST segment elevation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Combined end point",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Persistent ST segment depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Recurrent ST segment changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Presence of Q waves",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Preexisting pathologic Q waves or T wave inversion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Absence of Q waves after therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Biochemical markers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Infarct size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Reperfusion arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Procoagulant markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PREDICTION OF FAILED FIBRINOLYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H66248293\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/54\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/54|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/59/36787\" title=\"figure 1\">",
"      Factors for TIMI grade flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/9/29853\" title=\"figure 2\">",
"      TIMI flow time to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/40/16013\" title=\"figure 3\">",
"      Mortality after thrombolysis based on TIMI flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/52/10061\" title=\"figure 4\">",
"      TIMI flow and survival after thrombolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/0/21518\" title=\"figure 5\">",
"      TIMI frame count outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/59/10174\" title=\"figure 6\">",
"      ST segment resolution and mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/0/7182\" title=\"figure 7\">",
"      Prognosis of MI in relation to ST changes at 90 minutes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/52/39758\" title=\"figure 8\">",
"      ST resolution vs TIMI flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/23/27005\" title=\"figure 9\">",
"      ST segment resolution outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/2/33838\" title=\"figure 10\">",
"      Early ST segment shifts after thrombolysis predict outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/25/26013\" title=\"figure 11\">",
"      Infarct size mortality MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/45/4831\" title=\"figure 12\">",
"      Procoagulants outcome MI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/28/28101?source=related_link\">",
"      Biomarkers of cardiac injury other than troponins and creatine kinase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=related_link\">",
"      Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/24/11658?source=related_link\">",
"      Electrocardiogram in the diagnosis of myocardial ischemia and infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/26/4521?source=related_link\">",
"      Electrocardiogram in the prognosis of myocardial infarction or unstable angina",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22421?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in unstable angina and acute non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8634?source=related_link\">",
"      Management of failed fibrinolysis (thrombolysis) or threatened reocclusion in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12570?source=related_link\">",
"      Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29961?source=related_link\">",
"      Primary percutaneous coronary intervention versus fibrinolysis in acute ST elevation myocardial infarction: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_38_7787="Referral to gyn oncologist";
var content_f7_38_7787=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Referral of women with a pelvic mass to a gynecologic oncologist: ACOG guidelines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Premenopausal women (refer if any are present)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Very elevated CA 125 level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ascites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evidence of abdmonial or distant metastases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Postmenopausal women (refer if any are present)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Elevated CA 125 level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ascites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nodular or fixed pelvic mass",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evidence of abdominal or distant metastases",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    ACOG: American Congress of Obstetricians and Gynecologists.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     The role of the obstetrician&ndash;gynecologist in the early detection of epithelial ovarian cancer. Committee Opinion No. 477. American College of Obstetricians and Gynecologists. Obstet Gynecol 2011; 117:742.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_38_7787=[""].join("\n");
var outline_f7_38_7787=null;
var title_f7_38_7788="Molecular classification of CRC";
var content_f7_38_7788=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F77353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F77353&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Molecular classification of colorectal carcinoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chromosomal instability pathway (APC)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mismatch repair pathway",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Serrated pathway",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Hereditary (FAP) and sporadic",
"       </td>",
"       <td class=\"subtitle2\">",
"        Hereditary",
"       </td>",
"       <td class=\"subtitle2\">",
"        Hereditary",
"       </td>",
"       <td class=\"subtitle2\">",
"        Sporadic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CIMP status",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        High",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MSI status",
"       </td>",
"       <td>",
"        MSS",
"       </td>",
"       <td>",
"        MSI-H",
"       </td>",
"       <td>",
"        MSI-H",
"       </td>",
"       <td>",
"        MSI-L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chromosomal instability",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        ---",
"       </td>",
"       <td>",
"        ---",
"       </td>",
"       <td>",
"        ---",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        KRAS mutation",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +/-",
"       </td>",
"       <td>",
"        ---",
"       </td>",
"       <td>",
"        ---",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BRAF mutation",
"       </td>",
"       <td>",
"        ---",
"       </td>",
"       <td>",
"        ---",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MLH1 status",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Mutation",
"       </td>",
"       <td>",
"        Methylated",
"       </td>",
"       <td>",
"        Partial methylation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CIMP: CpG island methylator phenotype; MSS: microsatellite stability; MSI: microsatellite instability; MSI-H: high-level microsatellite instability; MSI-L: low-level microsatellite instability; +++: present; +/-: might or might not be present; ---: absent.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Cunningham, D, Atkins, W, Lenz, HJ, et al. Colorectal cancer. Lancet 2010; 375:1030. Copyright &copy; 2010. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_38_7788=[""].join("\n");
var outline_f7_38_7788=null;
var title_f7_38_7789="Meds for subacute LBP";
var content_f7_38_7789=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medications for chronic or subacute low back pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Drug",
"      </td>",
"      <td class=\"subtitle1\">",
"       Net benefit*",
"      </td>",
"      <td class=\"subtitle1\">",
"       Graded recommendation&sect;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Comments",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acetaminophen",
"      </td>",
"      <td>",
"       Small",
"      </td>",
"      <td>",
"       Suggested as first-line therapy&bull;",
"       <strong>",
"        (2B)",
"       </strong>",
"      </td>",
"      <td>",
"       Asymptomatic elevations of liver function tests at therapeutic doses.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Antidepressants",
"      </td>",
"      <td>",
"       Small",
"      </td>",
"      <td>",
"       Suggested as adjunctive therapy",
"       <strong>",
"        (2B)",
"       </strong>",
"      </td>",
"      <td>",
"       <p>",
"        Only tricyclic antidepressants have been shown effective for low back pain.",
"       </p>",
"       <p>",
"        No evidence on duloxetine or venlafaxine.",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Antiepileptic drugs",
"      </td>",
"      <td>",
"       Unable to estimate",
"      </td>",
"      <td>",
"       Suggest not using",
"       <strong>",
"        (2B)",
"       </strong>",
"      </td>",
"      <td>",
"       Gabapentin and topiramate evaluated in short-term trials, primarily in patients with radiculopathy.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Non-steroidal anti-inflammatory drugs",
"      </td>",
"      <td>",
"       Moderate",
"      </td>",
"      <td>",
"       Suggested as first-line therapy",
"       <strong>",
"        (2B)",
"       </strong>",
"      </td>",
"      <td>",
"       <p>",
"        May cause serious gastrointestinal and cardiovascular adverse events.",
"       </p>",
"       <p>",
"        Insufficient evidence to judge benefits and harms of aspirin or celecoxib for low back pain.",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Opioids",
"      </td>",
"      <td>",
"       Unable to estimate",
"      </td>",
"      <td>",
"       Suggest not using as first-line therapy",
"       <strong>",
"        (2B)",
"       </strong>",
"      </td>",
"      <td>",
"       No reliable data on risks of abuse or addiction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Skeletal muscle relaxants and benzodiazepines",
"      </td>",
"      <td>",
"       Unable to estimate",
"      </td>",
"      <td>",
"       Suggest not using",
"       <strong>",
"        (2C)",
"       </strong>",
"      </td>",
"      <td>",
"       The two higher-quality trials evaluated skeletal muscle relaxants not available in the US.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Based on evidence showing medication is more effective than placebo, and/or evidence showing medication is at least as effective as other medications or interventions thought to be effective, for one or more of the following outcomes: pain, functional status, or work status. Versus placebo, small benefit defined as 5-10 points on a 100-point Visual Analogue Scale (VAS) for pain (or equivalent), 1-2 points on the Roland Morris Disability Questionnaire (RDQ), 10-20 points on the Oswestry Disability Index (ODI), or a standardized mean difference (SMD) of 0.2-0.5. Moderate benefit defined as 10-20 points on a VAS for pain, 2-5 points on the RDQ, 10-20 points on the ODI, or a SMD of 0.5-0.8. Large benefit defined as &gt;20 points on a 100 point VAS for pain; &gt;5 points on the RDQ, &gt;20 points on the ODI, or a SMD of &gt;0.8.",
"     <br>",
"      &bull; Due to safety profile.",
"      <br>",
"       &sect; Grading:",
"       <br>",
"        <strong>",
"         1A",
"        </strong>",
"        - Strong recommendation. High quality evidence. Strong recommendation, can apply to most patients in most circumstances without reservation.",
"        <br>",
"         <strong>",
"          1B",
"         </strong>",
"         - Strong recommendation. Moderate quality evidence. Strong recommendation, likely to apply to most patients.",
"         <br>",
"          <strong>",
"           1C",
"          </strong>",
"          - Strong recommendation. Low quality evidence. Relatively strong recommendation; might change when higher quality evidence becomes available.",
"          <br>",
"           <strong>",
"            2A",
"           </strong>",
"           - Weak recommendation. High quality evidence. Weak recommendation, best action may differ depending on circumstances or patients or societal values.",
"           <br>",
"            <strong>",
"             2B",
"            </strong>",
"            - Weak recommendation. Moderate quality evidence. Weak recommendation, alternative approaches likely to be better for some patients under some circumstances.",
"            <br>",
"             <strong>",
"              2C",
"             </strong>",
"             - Weak recommendation. Low quality evidence. Very weak recommendation; other alternatives may be equally reasonable.",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_38_7789=[""].join("\n");
var outline_f7_38_7789=null;
var title_f7_38_7790="First-line TB drugs";
var content_f7_38_7790=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F55978%7EID%2F66493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=14\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F55978%7EID%2F66493&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=14\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Doses of first line antituberculosis drugs for adults*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Drug",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Preparation",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"4\">",
"       Doses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Daily",
"      </td>",
"      <td class=\"subtitle2\">",
"       1x/wk",
"      </td>",
"      <td class=\"subtitle2\">",
"       2x/wk",
"      </td>",
"      <td class=\"subtitle2\">",
"       3x/wk",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\" rowspan=\"1\">",
"       First-line drugs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Isoniazid",
"      </td>",
"      <td>",
"       Tablets (50 mg, 100 mg, 300 mg); elixir (50 mg/5 mL); aqueous solution (100 mg/mL) for intravenous or intramuscular injection",
"      </td>",
"      <td>",
"       5 mg/kg (300 mg)",
"      </td>",
"      <td>",
"       15 mg/kg (900 mg)",
"      </td>",
"      <td>",
"       15 mk/kg (900 mg)",
"      </td>",
"      <td>",
"       15 mg/kg (900 mg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Rifampin",
"      </td>",
"      <td>",
"       Capsule (150 mg, 300 mg); powder may be suspended for oral administration; aqueous solution for intravenous injection",
"      </td>",
"      <td>",
"       10 mg/kg (600 mg)",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       10 mg/kg (600 mg)",
"      </td>",
"      <td>",
"       10 mg/kg (600 mg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Rifabutin",
"      </td>",
"      <td>",
"       Capsule (150 mg)",
"      </td>",
"      <td>",
"       5 mg/kg (300 mg)",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       5 mg/kg (300 mg)",
"      </td>",
"      <td>",
"       5 mg/kg (300 mg)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Rifapentine",
"      </td>",
"      <td>",
"       Tablet (150 mg, film coated)",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       10 mg/kg (continuation phase) (600 mg)",
"      </td>",
"      <td>",
"       -",
"      </td>",
"      <td>",
"       -",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Pyrazinamide",
"      </td>",
"      <td>",
"       Tablet (500 mg, scored)",
"      </td>",
"      <td>",
"       Weight based dosing summarized in separate table",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ethambutol",
"      </td>",
"      <td>",
"       Tablet (100 mg; 400 mg)",
"      </td>",
"      <td>",
"       Weight based dosing summarized in separate table",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Doses per weight is based on ideal body weight. For purposes of this document adult dosing begins at age 15 years.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Blumberg, HM, Burman, WJ, Chaisson, RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dosing of second line antituberculosis drugs in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"10%\">",
"     </colgroup>",
"     <colgroup span=\"3\" width=\"30%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Daily adult dosage*",
"        <br/>",
"        (normal renal function)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Main adverse affects",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Levofloxacin",
"       </td>",
"       <td>",
"        1000 mg orally or IV",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        GI toxicity, CNS effects, rash, dysglycemia, tendonitis or tendon rupture, QT prolongation",
"       </td>",
"       <td>",
"        Potential choice when there are no suitable alternatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moxifloxacin",
"       </td>",
"       <td>",
"        400 mg orally or IV",
"       </td>",
"       <td>",
"        GI toxicity, CNS effects, rash, tendonitis or tendon rupture, QT prolongation, dysglycemia",
"       </td>",
"       <td>",
"        Potential choice when there are no suitable alternatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Capreomycin",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        15 mg/kg IM or IV (max 1 g)",
"       </td>",
"       <td>",
"        Auditory and vestibular toxicity, nephrotoxicity, electrolyte disturbances",
"       </td>",
"       <td>",
"        Avoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kanamycin",
"        <sup>",
"         &Delta;&loz;",
"        </sup>",
"       </td>",
"       <td>",
"        15 mg/kg IM or IV (max 1 g)",
"       </td>",
"       <td>",
"        Ototoxicity, nephrotoxicity",
"       </td>",
"       <td>",
"        Avoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amikacin",
"        <sup>",
"         &Delta;&loz;",
"        </sup>",
"       </td>",
"       <td>",
"        15 mg/kg IM or IV (max 1 g)",
"       </td>",
"       <td>",
"        Ototoxicity, nephrotoxicity",
"       </td>",
"       <td>",
"        Avoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Streptomycin",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        15 mg/kg IM or IV (max 1 g)",
"       </td>",
"       <td>",
"        Vestibular and ototoxicity, neurotoxicity, nephrotoxicity",
"       </td>",
"       <td>",
"        Avoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ethionamide",
"       </td>",
"       <td>",
"        15 to 20 mg/kg orally as a single daily dose or 2 divided doses (max 500 mg twice daily)",
"       </td>",
"       <td>",
"        <p>",
"         GI and hepatic toxicity, neurotoxicity, hypothyroidism, optic neuritis.",
"        </p>",
"        Pyridoxine 50 to 100 mg orally per day may be useful in preventing or reducing neurotoxicity.",
"       </td>",
"       <td>",
"        Potential choice when there are no suitable alternatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cycloserine",
"       </td>",
"       <td>",
"        10 to 15 mg/kg orally in 2 divided doses (max 500 mg twice daily)",
"       </td>",
"       <td>",
"        <p>",
"         Psychiatric symptoms, headaches, seizures.",
"        </p>",
"        Pyridoxine 50 mg (oral once per day) for every 250 mg of cycloserine may be useful in preventing or reducing neurotoxicity.",
"       </td>",
"       <td>",
"        Potential choice when there are no suitable alternatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Para-aminosalicylic acid",
"       </td>",
"       <td>",
"        8 to 12 g orally in 2 or 3 divided doses",
"       </td>",
"       <td>",
"        GI toxicity, malabsorption, hypersensitivity, hepatitis, hypothyroidism",
"       </td>",
"       <td>",
"        Potential choice when there are no suitable alternatives",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IM: intramuscular; IV: intravenous; GI: gastrointestinal; CNS: central nervous system; max: maximum.",
"     <br/>",
"     * Dosage may need to be adjusted for renal impairment.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Greater efficacy has been observed with administration of 1000 mg (compared with 500 mg) for treatment of multidrug-resistant tuberculosis.",
"     <br/>",
"     &Delta; Generally given 5 to 7 times per week (15 mg/kg, or a maximum of 1 g per dose) for an initial 2 to 4 months, and then (if needed) 2 to 3 times per week (20 to 30 mg/kg, or a maximum of 1.5 g per dose). For patients &gt;59 years old, dosage is reduced to 10 mg/kg (max 750 mg per dose). Dosage should be decreased if renal function is diminished.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     For patients who are overweight or obese, dose is based on ideal body weight or dosing weight (see UpToDate calculator). Adjust dose based on serum concentration monitoring for target trough &lt;1 mcg/mL and target peak of 56 to 64 mcg/mL for once daily administration.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with special permission from: Treatment Guidelines from The Medical Letter, April 2012; Vol. 10 (116):29.",
"     <a href=\"file://www.medicalletter.org\" target=\"_blank\">",
"      www.medicalletter.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_38_7790=[""].join("\n");
var outline_f7_38_7790=null;
var title_f7_38_7791="Facial changes Cushings PI";
var content_f7_38_7791=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F65766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F65766&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Changes caused by Cushing's syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 249px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cushing's syndrome can cause the face to become rounded, and fat to build up around the bottom of the neck. It can also cause more hair to grow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Williams Textbook of Endocrinology, 8th ed, Foster DW, Wilson JD (Eds), WB Saunders, Philadelphia, 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_38_7791=[""].join("\n");
var outline_f7_38_7791=null;
